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biochemically similar to mouse-derived species and were found to be toxic to primary neurons. Taken
together, these data provide evidence that dopamine-induced α-synuclein oligomers may underlie the
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ABSTRACT
THE TOXIC INTERACTION OF DOPAMINE AND ALPHA-SYNUCLEIN:
IMPLICATIONS FOR PARKINSON’S DISEASE
Danielle Emille Mor
Harry Ischiropoulos

Neurodegenerative disorders are characterized by the death of specific neuronal
populations and the aggregation of particular proteins into pathological inclusions. The
role of protein aggregation and the factors that govern neuronal susceptibility to disease
have remained unclear. In Parkinson’s disease (PD), the loss of dopamine producing
neurons in the substantia nigra (SN) leads to severe motor impairments, and the protein
α-synuclein is found aggregated in several brain regions including the SN. The goal of
this thesis was to investigate a possible mechanism for the vulnerability of dopaminergic
neurons: the interaction of α-synuclein with dopamine itself. While dopamine has been
suspected to contribute to cell death in PD by causing oxidative stress, I found using a
lentiviral approach that a long-term increase of dopamine levels in non-transgenic mice
was insufficient to produce dopamine neuron loss. In contrast, elevating dopamine in
mice expressing human α-synuclein resulted in progressive nigrostriatal degeneration and
an associated locomotor deficit. These findings demonstrate that dopamine toxicity is
dependent on α-synuclein. To explore a possible point of convergence of these two
factors, I examined the effects of dopamine on α-synuclein aggregation in the mouse
brain. This led to the novel observation that dopamine increases total steady-state levels
v

of α-synuclein oligomers and promotes modified oligomeric conformations. α-Synuclein
oligomers generated in the presence of dopamine in vitro were biochemically similar to
mouse-derived species and were found to be toxic to primary neurons. Taken together,
these data provide evidence that dopamine-induced α-synuclein oligomers may underlie
the susceptibility of dopaminergic neurons in disease.
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CHAPTER 1
INTRODUCTION

1

1.1 Introduction
Neurodegenerative diseases are clinically and pathologically distinct, and yet
share many fundamental features that suggest common underlying mechanisms.
Diseases such as Alzheimer’s (AD), Parkinson’s (PD), Huntington’s (HD) and
amyotrophic lateral sclerosis (ALS) are typically late-onset and progressive, leading to
debilitating cognitive and/or motor deficits. Despite differences in clinical presentation
and the specific neuronal populations that are lost, neurodegenerative disorders share a
common pathological hallmark, the presence of proteinaceous inclusions in the central
nervous system. The regional and subcellular localization of these lesions differs in each
disease, as well as the major protein constituents. In AD, extracellular senile plaques
consist of the peptide amyloid-β (Glenner and Wong, 1984), and intraneuronal
neurofibrillary tangles contain the microtubule-associated protein tau (Lee et al., 1991).
In PD and related disorders, the hallmark pathological substrates are Lewy bodies and
Lewy neurites, cytoplasmic inclusions containing the presynaptic protein α-synuclein
(Spillantini et al., 1997). Intranuclear aggregates in HD are comprised of the protein
huntingtin (DiFiglia et al., 1997), whereas the majority of ALS patients develop TDP-43
positive inclusions (Neumann et al., 2006).
Despite extensive research efforts, the relationship of aggregation and
neurodegeneration remains unclear.

The neuronal populations that harbor inclusion

pathology only partially overlap with those that undergo cell death, and the density of
inclusions is only weakly correlated with the severity of clinical symptoms (Ross and
Poirier, 2005).

While it was originally thought that large intracellular deposits

compromise neuronal health, more recently it has been recognized that inclusions may
2

serve a protective role as a sink for more toxic aggregation intermediates. Indeed, small
aggregates termed oligomers have emerged as potentially a major pathogenic species in
multiple neurodegenerative disorders (Kayed et al., 2003). The discovery of causative
genetic mutations in families afflicted with these disorders has allowed for the
development of genetic animal and cellular models, greatly advancing our understanding
of the molecular mechanisms involved in neurodegeneration. In many cases, the genes
linked to disease encode the characteristic proteins found aggregated within inclusions,
further implicating protein aggregation in disease pathogenesis (Lill and Bertram, 2011).
Continued investigation is required to uncover the complex interactions between protein
aggregates and cellular machinery that lead to neuron death, and to develop new therapies
to combat these devastating diseases for which there is currently no cure.

1.2 Synucleinopathies
α-Synuclein aggregation into insoluble filamentous inclusions is a central
pathological feature of diseases collectively referred to as synucleinopathies, including
PD, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). In 1912,
Fritz Heinrich Lewy published the first descriptions of intraneuronal proteinaceous
inclusions in PD patient brains (Lewy, 1912), which were later named after him
(Tretiakoff, 1919). In 1997, following the discovery of a PD-linked mutation in the gene
encoding α-synuclein (Polymeropoulos et al., 1997), it was found that Lewy bodies and
analogous deposits in neural projections, Lewy neurites, are robustly immunoreactive for
α-synuclein even in sporadic disease (Spillantini et al., 1997). These seminal findings
heralded a new era of research on the role of α-synuclein in neurodegenerative diseases.
3

1.2.1 α-Synuclein structure and function
α-Synuclein is a small (140 residues) highly conserved protein that is abundantly
expressed in brain and in part localized to presynaptic nerve terminals (Maroteaux et al.,
1988; Jakes et al., 1994; Iwai et al., 1995). The physiological functions of α-synuclein
appear to involve synaptic maintenance and plasticity (George et al., 1995; Withers et al.,
1997), regulation of synaptic vesicle pools (Murphy et al., 2000; Nemani et al., 2010),
and SNARE complex assembly (Chandra et al., 2005; Burré et al., 2010). Transgenic
mice lacking α-synuclein have normal neuronal and synaptic development, though subtle
deficits in dopamine release suggest a role in synaptic vesicle recycling (Abeliovich et
al., 2000; Cabin et al., 2002; Yavich et al., 2004). While the native conformation of αsynuclein is under debate (Weinreb et al., 1996; Bartels et al., 2011; Wang et al., 2011;
Fauvet et al., 2012a; Gould et al., 2014), its sequence and proximity to synaptic vesicles
suggest that interactions with vesicular membranes may be important for its biological
activity. Specifically, the N-terminal region contains seven imperfect repeats with a
consensus motif of KTKEGV, resembling the lipid binding domain of apolipoproteins
(George et al., 1995; Maroteaux et al., 1988). This region mediates acquisition of αhelical structure that occurs upon α-synuclein binding to lipid membranes in vitro
(Davidson et al., 1998). Amino acids 61-95 make up the hydrophobic NAC (nonamyloid-β component of Alzheimer’s disease amyloid) domain (Uéda et al., 1993), which
is necessary for aggregation (Giasson et al., 2001). The C-terminal region is highly
acidic and contains known sites of protein-protein interactions, metal binding, and posttranslational modifications (Uversky et al., 2001a; Woods et al., 2007; Oueslati et al.,
2010). For a detailed review of α-synuclein native structure and function see Chapter 3.
4

1.2.2 α-Synuclein pathology in disease
Significant clinical and pathological overlap between synucleinopathies suggests
they may share common underlying mechanisms driven by α-synuclein toxicity. PD and
MSA are primarily movement disorders, characterized by resting tremor, muscle rigidity,
bradykinesia, and postural instability (collectively termed parkinsonism) (Hoehn and
Yahr, 1967). DLB is also defined by parkinsonian symptoms, as well as prominent
dementia that develops within one year of motor dysfunction (McKeith et al., 2005).
While PD and DLB have largely indistinguishable Lewy body pathology in brainstem
nuclei, DLB more commonly involves widespread cortical Lewy bodies, which may
underlie the presentation of dementia (Kosaka, 1978; Lennox et al., 1989; McKeith et al.,
1996; Spillantini et al., 1997). Senile plaques characteristic of AD are usually present in
the cortex in DLB (Lennox et al., 1989), and conversely AD patients often have Lewy
bodies in the amygdala (Kotzbauer et al., 2001). MSA is an atypical synucleinopathy in
that α-synuclein-positive inclusions are present in oligodendrocytes rather than neurons,
and are termed glial cytoplasmic inclusions (GCIs) (Papp et al., 1989; Wakabayashi et
al., 1998; Spillantini et al., 1998a; Tu et al., 1998). GCIs are found in diverse areas of the
brain, including the neocortex, hippocampus, midbrain, brainstem, and cerebellum
(Arima et al., 1992; Duda et al., 2000).
Inclusion pathology has been extensively studied both histologically and
biochemically from postmortem diseased human brain. Lewy bodies are classically
defined as eosinophilic structures with a dense core surrounded by a diffuse halo;
however, while this description is suitable for brainstem inclusions, cortical Lewy bodies
have a less distinct appearance (Pollanen et al., 1993; Forno, 1996). α-Synuclein, but
5

not the related β-synuclein, has been identified as an integral component of Lewy bodies
using a multitude of antibodies (Spillantini et al., 1997; 1998b; Takeda et al., 1998; Baba
et al., 1998; Irizarry et al., 1998; Giasson et al., 2000a; Crowther et al., 2000). By
electron microscopy, α-synuclein filaments from diseased brain appear unbranched, are
typically 5-10 nm in width, and can reach hundreds of nm in length (Spillantini et al.,
1998b). Several modifications have been identified in α-Synuclein isolated from Lewy
bodies, including phosphorylation at Ser-129 and Ser-87, ubiquitination at Lys-12, Lys21, and Lys-23, and C-terminal truncations (Fujiwara et al., 2002; Hasegawa et al., 2002;
Anderson et al., 2006; Paleologou et al., 2010). In addition, tyrosine-nitrated α-synuclein
is widespread in the brains of synucleinopathy patients (Giasson et al., 2000b). For a
review of α-synuclein post-translational modifications in vivo and in vitro, see Chapter 3.
Lewy body inclusions also contain other proteins, including neurofilaments, proteasomal
subunits, and synaptophysin (Goldman et al., 1983; Schmidt et al., 1991; Ii et al., 1997;
Takeda et al., 1998), as well as lipids (Gai et al., 2000).

1.2.3 α-Synuclein aggregation pathway
The fibrillar morphologies of synucleinopathy lesions have been recapitulated in
numerous studies using recombinant α-synuclein in vitro. Like amyloids in AD and other
diseases, α-synuclein is able to form amyloid-like fibrils, which are rich in β-pleated
sheets and produce characteristic signals upon binding Thioflavin T and Congo Red dyes.
Recombinant α-synuclein fibrils have been observed by numerous imaging and
biochemical methodologies, including electron and atomic force microscopy, circular
dichroism,

solid-state

nuclear

magnetic resonance and infrared spectroscopy, and
6

gel electrophoresis (Conway et al., 1998; 2000a; Hashimoto et al., 1998; Giasson et al.,
1999; Serpell et al., 2000; Tuttle et al., 2016). In vitro, the formation of fibrils follows a
classical polymerization reaction, including a lag phase with little detectable fibril
formation, followed by a growth phase with rapid polymerization. The rate-limiting step
in α-synuclein fibrillization is thought to be the initial formation of a nucleus, likely an
oligomer or small polymer of α-synuclein molecules (Wood et al., 1999; Uversky et al.,
2001b). A schematic of the aggregation pathway of α-synuclein is depicted in Figure 1.1.

1.3 Parkinson’s disease
PD is the most common age-associated movement disorder, affecting 7 million
people worldwide and predicted to significantly increase in prevalence as the population
ages (Van Den Eeden et al., 2003; de Lau and Breteler, 2006). The parkinsonian motor
features that were first described by James Parkinson in 1817 arise from progressive loss
of dopaminergic neurons in the substantia nigra pars compacta (SN) (Parkinson, 1817;
Tretiakoff, 1919; Hassler, 1938). While diagnosis of PD is contingent on the presentation
of motor signs, it is increasingly recognized that the PD clinical profile involves non7

motor features as well.

Sleep disturbances, autonomic dysfunction, hyposmia, and

depression may appear decades prior to the onset of motor impairment (Lim et al., 2009).
Dementia is also common, typically in advanced PD (Reid et al., 2011). The loss of
extranigral neuronal populations may underlie non-motor symptoms. In the brainstem,
noradrenergic neurons of the locus coeruleus are particularly affected. Cholinergic cells
are also lost, both in the dorsal motor nucleus of the vagus in the brainstem and nucleus
basalis of Meynert in the basal forebrain (Forno, 1996). PD is therefore considered a
complex disorder involving multiple brain regions and neurotransmitter systems.

1.3.1 Basal ganglia dysfunction in PD
The death of dopaminergic cells in PD leads to a severe depletion of dopamine at
the main site of SN innervation, the dorsal striatum (Ehringer and Hornykiewicz, 1960).
The SN and striatum are found within the basal ganglia, a group of subcortical structures
that serve as a critical regulator of motor output. The classical model of basal ganglia
circuitry describes three major pathways: the direct pathway, which is thought to promote
selected motor programs, and the indirect and hyperdirect pathways, which are thought to
simultaneously oppose competing motor programs (Wichmann et al., 2011). As depicted
in Figure 1.2, the direct pathway involves cortical excitation of striatal neurons, which in
turn disinhibit thalamocortical circuits resulting in greater excitation of motor neurons.
The indirect pathway instead disinhibits the subthalamic nucleus, causing excitation of
the globus pallidus interna and suppression of thalamocortical activity (Albin et al., 1989;
DeLong, 1990). The hyperdirect pathway bypasses the striatum and directly excites the
subthalamic nucleus, dampening the activity of motor neurons (Nambu et al., 2000).
8

Dopamine serves as an important modulator of this complex circuitry. Spiny
projection neurons in the striatum express G-protein coupled dopamine receptors of
either the D1- or D2-type. Neurons in the direct pathway express D1-type receptors,
which mediate an increase in intrinsic excitability upon activation by dopamine, and
promote long-term potentiation. Indirect pathway neurons express D2-type receptors and
have the opposite response when bound by dopamine, promoting long-term depression.
The loss of striatal dopamine in PD is therefore thought to result in reduced activity of the
direct pathway and increased activity of the indirect pathway, accounting for the overall
reduction of movement (Surmeier et al., 2014). While this model of basal ganglia
circuitry and its dysfunction in PD has proved useful, it was recently proposed that the
direct and indirect pathways may actually be much more integrated both structurally and
functionally (Calabresi et al., 2014).

1.3.2 Genetics of PD
While

PD

is

rarely

inherited (~10% of all cases),
genetic mutations identified in
families with the disease offer
insight into the mechanisms
underlying the sporadic disorder. Several genes are now
linked with highly penetrant,
monogenic
9

forms

of

PD,

including the gene encoding α-synuclein, SNCA, as well as LRRK2, Parkin, DJ-1,
PINK1, UCHL1, ATP13A2 and VPS35, and numerous genetic risk factors have
additionally been identified (Hernandez et al., 2016). The A53T missense mutation in
SNCA was the first genetic link identified, specifically in autosomal dominant early-onset
PD (Polymeropoulos et al., 1997). Since this discovery, additional mutations in SNCA
have been found to cause PD: A30P, E46K, H50Q, G51D, and most recently A53E
(Krüger et al., 1998; Zarranz et al., 2004; Proukakis et al., 2013; Lesage et al., 2013;
Pasanen et al., 2014). These mutants are all located within the N-terminal region that is
required for membrane binding, and in many cases exhibit altered aggregation kinetics
and lipid interactions in vitro (Conway et al., 1998; Jensen et al., 1998; Giasson et al.,
1999; Choi et al., 2004; Ghosh et al., 2014; Khalaf et al., 2014; Fares et al., 2014).
Multiplications of the SNCA gene locus also cause early-onset PD, with increasing copy
number correlating with earlier age of onset and greater severity of symptoms, suggesting
that increased expression of wild type (WT) α-synuclein is detrimental (Singleton et al.,
2003; Chartier-Harlin et al., 2004; Ferese et al. 2015).
Mutations in LRRK2 result in autosomal dominant PD and are the most common
cause of familial cases (Zimprich et al., 2004; Paisan-Luiz et al., 2004). The G2019S
mutation is the most well-studied; it is located in the kinase domain of LRRK2 and
results in increased kinase activity. At present, the pathophysiological mechanisms of
LRRK2 toxicity are unclear (Hernandez et al., 2016). Several of the other genes linked to
PD induce a early-onset, autosomal recessive form of the disease (Kitada et al., 1998,
Valente et al., 2004, Bonifati et al., 2003) and are functionally related in the cellular
response to mitochondrial damage. Parkin is
10

an

E3

ubiquitin

ligase

that

is

translocated to defective mitochondria where it is phosphorylated by PINK1.

This

stimulates parkin to ubiquitinate multiple substrates, leading to the clearance of
mitochondria by autophagy (Park et al., 2006; Clark et al., 2006). DJ-1 may also function
in this pathway, though its role is much less clear. It is thought that mutations in Parkin,
PINK1, and DJ-1 are responsible for disease through a loss-of-function mechanism
(Goedert et al., 2013). Interestingly, autosomal recessive PD is not characterized by
Lewy body pathology, possibly due to the young age of onset (Hernandez et al., 2016).
Further investigation is necessary to better understand the role of α-synuclein in this form
of PD.

1.3.3 Genetic animal models of α-synuclein toxicity
α-Synuclein expression in animal model systems has provided key insights into
the complex relationship between aggregation and neurodegeneration. In monkeys and
rats, viral-mediated expression of WT or A53T mutant human α-synuclein in the SN
resulted in a progressive neurological disease that recapitulated the cardinal features of
PD. The formation of intracellular α-synuclein positive inclusions and neuritic pathology
was accompanied by the selective loss of 30-80% of dopaminergic neurons and the
development of motor deficits (Lo Bianco et al., 2002; Kirik et al., 2002; 2003).
Similarly, expression of A30P human α-synuclein in the rat SN caused dense α-synuclein
accumulations and over 50% loss of dopamine neurons. Motor impairments were not
detected in these rats, however (Klein et al., 2002), consistent with a threshold of about
70% neuron loss for movement symptoms to appear in humans (Dunnett and Bjorklund,
1999).
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Efforts to model PD by transgenic overexpression of α-synuclein in mice have
yielded mixed results.

Expression of WT α-synuclein under the PDGF-β promoter

resulted in atypical non-fibrillar α-synuclein inclusions and reduced TH immunoreactivity in the striatum without overt dopaminergic cell loss (Masliah et al., 2000). In
mice expressing human WT or familial mutants (A30P, E46K, or A53T) of α-synuclein
under the PrP promoter, the SN was consistently spared of both neurodegeneration and αsynuclein inclusion pathology, despite the development of Lewy body-like inclusions in
other regions specifically in A53T transgenic mice (Giasson et al., 2002; Lee et al., 2002;
Gispert et al., 2003; Gomez-Isla et al., 2003; Yavich et al., 2005; Martin et al., 2006;
Emmer et al., 2011). Similarly, Thy1-driven expression of human A30P α-synuclein did
not result in histopathological changes or neuron loss in the SN, possibly due to low
levels of transgene expression (Rathke-Hartlieb et al., 2001; Neumann et al., 2002).
Targeting WT, A30P, or A53T human α-synuclein expression specifically to
dopaminergic neurons using the TH promoter was insufficient to produce either
nigrostriatal degeneration or Lewy body-like α-synuclein pathology (Rathke-Hartlieb et
al., 2001; Matsuoka et al., 2001; Richfield et al., 2002).

Greater success inducing

dopaminergic cell death was achieved using bacterial artificial chromosome transgenic
mice expressing human WT α-synuclein (Janezic et al., 2013) or by conditional
expression of human WT or A53T α-synuclein (Nuber et al., 2008; Lin et al., 2012).
(The previous paragraph is taken from Mor et al., manuscript under revision).
Invertebrates have offered simple yet powerful platforms for conducting
mechanistic studies of α-synuclein toxicity. In flies, targeted expression of WT, A30P, or
A53T human α-synuclein in the nervous system produces filamentous α-synuclein
12

inclusions, neurodegeneration of dopamine cells, and an impairment in climbing ability
(Feany et al., 2000). Co-expression of α-synuclein with the chaperone Hsp70 was found
to rescue neuron death without reducing inclusion pathology, suggesting that the presence
of inclusions can be uncoupled from toxicity. Furthermore, co-expression of a dominantnegative mutant of Hsp70 with α-synuclein resulted in accelerated degeneration,
emphasizing the role of chaperone activity in maintaining neuronal health (Auluck et al.,
2002). In another study, expressing non-fibrillogenic α-synuclein lacking residues 71-82
was non-toxic to dopamine neurons, unlike WT α-synuclein, while aggregation-prone
truncation mutants exacerbated toxicity (Periquet et al., 2007). C. elegans expressing
human α-synuclein in dopaminergic neurons have exhibited variable phenotypes. In
some cases, WT or A53T α-synuclein transgenic worms showed dopamine neuron loss
(Lakso et al., 2003; Cao et al., 2010), whereas in another study, neurite degeneration
without overt cell loss was reported in WT, A30P, and A53T worms (Kuwahara et al.
2006). Motor deficits were sometimes observed and could be rescued by administration
of dopamine (Kuwahara et al. 2006; Cao et al., 2010). Finally, there is some evidence for
α-synuclein accumulations in these worms (Lakso et al., 2003; Kuwahara et al. 2006);
however it is unclear whether these structures are the result of α-synuclein aggregation.

1.3.4 Prion-like spread of α-synuclein pathology in PD
The progressive buildup of α-synuclein pathology in PD is suggestive of the
spread of disease agent(s), potentially originating in the gut and ultimately reaching the
central nervous system. Evidence suggests that early in the disease course, α-synuclein
positive inclusions form in the enteric nervous system (Braak et al., 2006). The
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vagal nerve serves as a major connection between the brain and the periphery, and
consistent with cell-to-cell transmission of pathology, the dorsal motor nucleus of the
vagus is among the earliest brain regions to become affected in PD (Braak et al., 2003).
Braak and colleages have defined six stages of PD based on the stereotypical distribution
of Lewy pathology. In the initial stages, in addition to the dorsal motor nucleus, the
anterior olfactory nucleus develops α-synuclein positive inclusions, as well as the raphe
nuclei and locus coeruleus. As PD advances, the midbrain becomes involved and finally
cortical regions such as sensory association areas (Braak et al., 2003). The development
of Lewy pathology may account for disease symptoms, in that inclusions are usually
present in the SN by the time motor dysfunction has manifested, and neocortical lesions
occur in late stages often accompanied by dementia (Goedert et al., 2013).
Several lines of evidence support prion-like transmission of α-synuclein in PD
and other neurodegenerative diseases (see Table 1). Post-mortem studies of PD patients
who received fetal mesencephalic grafts into the striatum showed that 11-16 years
following transplantation, grafted neurons contained Lewy body-like α-synuclein
inclusions (Li et al., 2008; Kordower et al., 2008). Given the young age of the grafted
cells, it is unlikely that pathology developed independent of exposure to α-synuclein
and/or other factors from diseased host tissue. In animal models, intracerebal inoculation
of recombinant α-synuclein pre-formed fibrils (PFFs), brain tissue from symptomatic
A53T α-synuclein transgenic mice, or brain tissue from synucleinopathy patients results
in widespread deposition of Lewy body-like α-synuclein inclusions often accompanied
by neurodegeneration and motor deficits. Moreover, it appears that, regardless of the site
of injection, aggregation propagates along synaptic connections and requires the
14

presence of endogenous α-synuclein (Luk et al., 2012a; 2012b; Masuda-Suzukake et al
2014; Watts et al., 2013; Recasens et al., 2013; Paumier et al., 2015; Sacino et al., 2014b;
Peelaerts et al., 2015). Several studies have also demonstrated the spread of α-synuclein
pathology from peripheral sites to the central nervous system, using intravenous
(Peelaerts et al., 2015), intramuscular (Sacino et al., 2014a), or intraperitoneal (Breid et
al., 2016) injections of recombinant α-synuclein aggregates into rodents. α-Synuclein
aggregation in vitro is also prion-like, exhibiting self-templated replication or ‘seeding’
via the repeated conversion of soluble protein into misfolded conformations (Conway et
al., 1998; Wood et al., 1999).
While these studies provide compelling evidence that aggregated α-synuclein is
sufficient to induce neurological disease bearing the hallmarks of synucleinopathies, even
in otherwise healthy non-transgenic animals, many questions still remain. The injection
of α-synuclein PFFs into mouse brain does not always lead to the spreading of pathology
(Sacino et al., 2013; 2014b), indicating that host-dependent susceptibility must be further
explored. Also, the induction of pathology may not require that the initiating α-synuclein
agent be fibrillized, as recombinant monomeric α-synuclein and mutant α-synuclein
lacking amino acids 71-82 in the NAC domain were able to produce inclusions in some
recipient animals (Sacino et al., 2013; 2014a; Paumier et al., 2015). Finally, it is possible
that factors other than α-synuclein contribute to inclusion formation, since spinal cord
tissue from non-transgenic mice or mice lacking endogenous α-synuclein was able to
induce pathology following intracerebral injection (Sacino et al., 2016).
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Table 1.1: Major evidence for prion-like transmission of α-synuclein (agent) in cell
culture and animal models (host).
Agent
Recombinant
human α-synuclein
oligomers and
PFFs of two
distinct strains
(fibrils or ribbons)

Recombinant
human and mouse
α-synuclein PFFs

PD tissue from SN
containing
insoluble LBs

Host
NonTg and human
α-synuclein
expressing rats,
injected into SN

Findings
By 4 mpi, only ribbons induced abundant
α-synuclein aggregation. Nigrostriatal
degeneration was dependent on α-synuclein
expression and was most severe for fibrils.
Fibrils also induced motor impairment.

NonTg rats, injected intravenously
Non-symptomatic
A53T, WT human
α-synuclein Tg
mice injected into
hindlimb muscle
Macaque monkeys,
injected into SN or
striatum

By 4 mpi, α-synuclein positive inclusions
detected in spinal cord and cortex.
By 2-4 mpi, A53T Tg mice developed widespread α-synuclein aggregation in the central
nervous system and motor deficits. By 12 mpi,
WT Tg mice developed α-synuclein pathology
without motor deficit.
By 9 mpi, loss of striatal terminals. By 14
mpi, dopamine neuron death and diffuse
α-synuclein deposits in SN.

NonTg mice,
injected into SN

By 4 mpi, loss of striatal terminals, dopamine
neuron death in SN, diffuse accumulations
containing phosphorylated α-synuclein in SN.
By ~3-4 mpi, neurological disease onset and
widespread aggregates containing phosphorylated α-synuclein.

MSA basal ganglia
tissue containing
insoluble GCIs

Non-symptomatic
A53T human αsynuclein Tg mice,
injected into cortex

Brain tissue from
symptomatic A53T
human α-synuclein
Tg mice
DLB brain tissue
containing insoluble α-synuclein

Non-symptomatic
A53T human αsynuclein Tg mice,
injected into cortex
NonTg mice,
injected into SN

Recombinant
human and mouse
α-synuclein PFFs
Recombinant
human α-synuclein
PFFs of two
distinct strains
(A or B)

NonTg mice,
injected into SN

Recombinant
mouse α-synuclein
PFFs

NonTg mice,
injected into
striatum

Mutant tau Tg
mice, injected into
hippocampus
Primary neurons
from NonTg or
mutant tau Tg mice

Reference
Peelaerts
et al.,
2015

Sacino et
al., 2014a

Recasens
et al.,
2013

Watts et
al., 2013

By ~6-7 mpi, neurological disease onset and
widespread aggregates containing phosphorylated α-synuclein.
By 15 mpi, widespread aggregates containing
phosphorylated α-synuclein

By 15 mpi, widespread aggregates containing
phosphorylated α-synuclein, without
accompanying neuron loss or motor deficit
At 3, 6, and 9 mpi, strain B more efficiently
cross-seeded tau than strain A.

Strain A was toxic, seeded abundant αsynuclein aggregation without cross-seeding
tau. Strain B was non-toxic, cross-seeded tau,
seeded α-synuclein less efficiently than A.
By 1 mpi, widespread endogenous αsynuclein aggregation. By 3 and 6 mpi, further
spread of aggregation, neuron death in SN,
and motor deficits.
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MasudaSuzukake
et al.,
2013

Guo et al.,
2013

Luk et al.,
2012b

Brain tissue from
symptomatic A53T
human α-synuclein
Tg mice

Non-symptomatic
A53T human αsynuclein Tg mice,
injected into cortex
or striatum

Accelerated neurological disease onset,
widespread aggregates containing phosphorylated α-synuclein, reduced survival

Recombinant
human α-synuclein
PFFs

Non-symptomatic
A53T human αsynuclein Tg mice,
injected into cortex
or striatum
Mouse fetal midbrain neurons, injected into striatum

Accelerated neurological disease onset,
widespread aggregates containing phosphorylated α-synuclein, reduced survival

WT human αsynuclein Tg mice

By 6 mpi, human α-synuclein from Tg mice
detected in grafted cells

Recombinant
α-synuclein PFFs,
oligomers, or
monomers

WT human αsynuclein Tg mice,
injected into cortex

By 1 day post-injection with PFFs or oligomers, intracellular puncta of α-synuclein.
Diffuse α-synuclein 1 dpi with monomers.

HEK or SH-SY5Y
cultures expressing
tagged α-synuclein,
conditioned media

HEK or SH-SY5Y
cultures expressing
different tag on
α-synuclein

Up to 14 days in culture, cells containing
double-labeled α-synuclein were detected

Recombinant
α-synuclein PFFs,
oligomers, or
monomers
Recombinant
human α-synuclein
PFFs

HEK cultures

By 3 hours post-treatment, exogenous αsynuclein was detected in cells regardless of
aggregation state administered

Primary neurons
from NonTg mice

WT human αsynuclein Tg mice

Mouse neuronal
stem cells, injected
into hippocampus

By 14 days post-treatment, exogenous
α-synuclein was internalized by cells, seeded
aggregation of endogenous α-synuclein, and
induced synaptic dysfunction and cell death
Up to 1 mpi, human α-synuclein detected in
non-fibrillar aggregates in grafted stem cells,
and markers of apoptosis

SH-SY5Y cultures
expressing human
α-synuclein, or
conditioned media
Recombinant
human α-synuclein
PFFs

Luk et al.,
2012a

Hansen et
al., 2011

VolpicelliDaley et
al., 2011
Desplats
et al.,
2009

Primary neurons or Up to 3 days in culture, detected intracellular
neuronal stem cells aggregates containing exogenous α-synuclein,
from mice or rats,
and markers of apoptosis
or SH-SY5Y cells
QBI-HEK, HeLa,
By 1 day post-treatment, exogenous αLuk et al.,
and SH-SY5Y
synuclein seeded aggregation of endogenous
2009
cultures expressing α-synuclein
human α-synuclein
Abbreviations: DLB, Dementia with Lewy bodies; GCI, glial cytoplasmic inclusion; LB, Lewy body; mpi,
months post-injection; MSA, multiple system atrophy; NonTg, non-transgenic; PD, Parkinson’s disease;
PFF, pre-formed fibrils; SN, substantia nigra; Tg, transgenic; WT, wild type.
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1.3.5 Pharmacologic therapies
Efforts to treat PD patients have centered on restoring dopaminergic signaling in
the striatum. Administration of the dopamine precursor, L-3,4-dihydroxyphenylalanine
(L-DOPA), was the first treatment developed for PD (Birkmayer and Hornykiewicz,
1961) and remains the most effective therapy to date.

However, prolonged use of

L-DOPA can have significant side effects, such as motor fluctuations and dyskinesia
(Olanow, 2015).

Other dopamine replacement therapies include dopamine receptor

agonists and inhibitors of dopamine metabolism (Kakkar et al., 2015). While these
therapeutic strategies can provide symptomatic relief, there is currently no cure for the
relentless loss of dopaminergic neurons in PD.

1.4 Dopamine as a neurotoxic molecule
Despite the clinical benefit of augmenting dopamine levels in PD patients, it has
long been suspected that dopamine may in fact contribute to the development of disease
(Fahn and Cohen, 1992; Jenner and Olanow, 1996; Stokes et al., 1999). Dopamine can
have many fates within the synapse, including release into the synaptic cleft, reuptake
into the presynaptic terminal for recycling, degradation by enzyme-catalyzed oxidation,
non-enzymatic auto-oxidation, and deposition into neuromelanin, the pigmented structure
for which the SN is named. The enzyme- or metal-catalyzed oxidation of dopamine can
generate cytotoxic quinones, hydrogen peroxide, and oxyradicals (Graham 1978), raising
important questions as to the role of dopamine in the degeneration of dopaminergic
neurons.

18

1.4.1 Dopamine synthesis and metabolism
Dopamine is synthesized in the cytosol from the amino acid L-tyrosine. The first
step in this reaction is rate-limiting; the enzyme tyrosine hydroxylase (TH) catalyzes the
conversion of L-tyrosine to L-DOPA using molecular oxygen and tetrahydrobiopterin as
cofactors. L-DOPA is converted to dopamine by aromatic amino acid decarboxylase
(AADC), generating carbon dioxide as a byproduct. The end-product, dopamine, serves
to regulate its own levels through feedback inhibition of TH (Nagatsu et al., 1964; Levitt
et al., 1965). Two residues, Arg-37 and Arg-38, in the N-terminal regulatory domain of
TH are required for this inhibition.

Mutation of these residues to Glu-37, Glu-38

significantly increases the catalytic activity of TH (Nakashima et al., 2002), which was
exploited in the current work to achieve unregulated elevation of dopamine levels.
Upon synthesis, dopamine is immediately packaged into synaptic vesicles by the
vesicular monoamine transporter 2 (VMAT2) (Erickson et al., 1992). VMAT2 is coupled
to a vesicular ATPase that generates a proton gradient, resulting in the pH within synaptic
vesicles of ~5.6 (Johnson and Scarpa, 1976; Casey et al., 1977). The acidic environment
facilitates neurotransmitter packaging, as two protons are exchanged for each molecule of
dopamine (Knoth et al., 1981), and also prevents dopamine from becoming oxidized.
Upon stimulation by an action potential, synaptic vesicles loaded with neurotransmitter
fuse with the presynaptic membrane and dopamine is released into the synaptic cleft.
Dopamine can then bind to D1- or D2-type postsynaptic receptors, as well as D2-type
presynaptic autoreceptors, and get recycled back into the presynaptic neuron by the
dopamine transporter (DAT) (Segura-Aguilar et al., 2014; Surmeier et al., 2014; Ford,
2014).
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Dopamine degradation is achieved by enzyme-catalyzed oxidation, which
necessarily produces potentially toxic aldehydes and peroxides.

Both in the nerve

terminal and extracellularly, monoamine oxidase (MAO) catalyzes the oxidative
deamination of dopamine into 3,4-dihydroxyphenylacetaldehyde (DOPAL), generating
hydrogen peroxide as a byproduct. DOPAL, a recognized neurotoxin (Burke et al., 2003;
Goldstein et al., 2013), is further oxidized to the non-toxic 3,4-dihydroxyphenylacetate
(DOPAC) by aldehyde dehydrogenase.

Extracellularly, DOPAC is converted to

homovanillic acid (HVA) by catechol-O-methyl transferase (COMT). COMT can also
act directly on dopamine to generate 3-methoxytyramine, which can in turn be
metabolized to HVA by extracellular MAO and aldehyde dehydrogenase (Segura-Aguilar
et al., 2014).

1.4.2 Dopamine auto-oxidation and antioxidant defenses
Dopamine that is not degraded or
packaged into synaptic vesicles is able to
auto-oxidize in the cytosol,
electron-deficient

quinones

generating

and

reactive

oxygen species (Graham 1978; Smythies et
al., 1998; Sulzer et al., 2000).

Dopamine

contains a catechol moiety (vicinal hydroxyls
on an aromatic ring) which can readily
donate two electrons to form dopamine-o-
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quinone (see Figure 1.3). If the electron acceptor is molecular oxygen, this generates
superoxide anion radicals. Dopamine-o-quinone can undergo deprotonation of the amine
group and cyclization to generate leukoaminochrome, which can further oxidize to form
the quinone, aminochrome. The rearrangement of aminochrome to 5,6-dihydroxyindole
is followed by oxidation to 5,6-indolequinone and polymerization to form neuromelanin.
Neuromelanin is an insoluble, granular structure that is thought to be a protective
mechanism for the sequestration of reactive derivatives of oxidized dopamine (Sulzer et
al., 2000). However, the observation that pigmented midbrain neurons are preferentially
lost in PD (Hirsch et al., 1988) suggests that neuromelanin and/or its precursors could
directly contribute to neuronal injury.
In addition to being deposited in neuromelanin, the products of dopamine
oxidation can be cleared by antioxidant enzymes and oxidant scavengers. Superoxide
radicals are converted to hydrogen peroxide and molecular oxygen by superoxide
dismutases (SODs). SODs are metalloenzymes localized to the cytoplasm (copper- and
zinc-containing SOD) and mitochondrial matrix (manganese-containing SOD) (McCord
and Fridovich, 1969). Glutathione peroxidase removes hydrogen peroxide by oxidizing
glutathione, and reduced glutathione is restored by glutathione reductase. Alternatively,
hydrogen peroxide can be broken down to molecular oxygen and water by catalase (Fahn
and Cohen, 1992). There is some evidence that dopamine quinones may be removed via
conjugation to glutathione, either spontaneously or catalyzed by glutathione Stransferases (Baez et al., 1997).

Conjugation of dopamine-o-quinone to glutathione

forms 5-S-glutathionyl dopamine, which is degraded to 5-S-cysteinyldopamine. The
latter product has been detected in human basal ganglia (Rosengren et al., 1985).
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1.4.3 The role of dopamine in oxidative stress
Due to the propensity of dopamine to auto-oxidize and its normal clearance via
oxidative metabolism, neurons in the SN are thought to be at high risk of oxidative stress.
Oxidative stress occurs when the concentration of oxidants exceeds the antioxidant
buffering capacity of the cell. Oxidants such as dopamine quinones, hydrogen peroxide,
and oxyradicals can damage all major classes of macromolecules, potentially leading to
cellular dysfunction and death (Fahn and Cohen, 1992; Jenner and Olanow, 1996; Stokes
et al., 1999). Several studies have identified markers of oxidative stress in postmortem
PD brain tissue. In the SN, polyunsaturated fatty acid content was found to be reduced
compared with other brain regions and tissue from controls, while products of lipid
peroxidation including malondialdehyde as well as 4-hydroxynonanol protein adducts
were increased (Dexter et al., 1989a; Yoritaka et al., 1996). Lewy bodies exhibit robust
immunoreactivity for protein nitration, including specifically nitrated α-synuclein (Good
et al., 1998; Giasson et al., 2000), and oxidatively modified nucleic acids are present in
SN neurons as well (Zhang et al., 1999).
The SN contains high concentrations of iron (Hallgren and Sourander, 1958),
putting this region at risk for both iron-catalyzed dopamine oxidation and production of
highly toxic hydroxyl radicals. Ferric iron (Fe3+) can catalyze the formation of dopamine
quinones and, once it is reduced to ferrous iron (Fe2+), can react with hydrogen peroxide
via the Fenton reaction to produce hydroxyl radical. In the presence of superoxide
radical, Fe2+ can be continually regenerated from Fe3+ in a dangerous cycle of HaberWeiss type reactions (Fahn and Cohen, 1992). PD patients have increased total iron and
specifically Fe3+ in SN relative to healthy controls, whereas glutathione levels are
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decreased (Sofic et al., 1988; Riederer et al., 1989; Dexter et al., 1989b; 1991). These
alterations are consistent with increased potential for iron-catalyzed oxidation reactions,
coupled with a reduced capacity of the antioxidant response.
Dopamine quinones are potentially neurotoxic via the covalent adduction to
cysteine sulfhydryl groups. Cysteines are often located in the active site of proteins, and
adduction may therefore irreversibly impair protein function (Sulzer et al., 2000).
Catecholamine cysteinyl adducts are selectively increased in the SN of PD patients,
though it is unknown if this is due to L-DOPA therapy (Spencer et al., 1998). The
protein targets of dopamine modification have been explored in various model systems
(Segura-Aguilar et al., 2014). Proteomic analysis was performed on isolated rat brain
mitochondria and SH-SY5Y cells that were exposed to radiolabeled dopamine or
dopamine quinone. A subset of mitochondrial proteins as well as the PD-linked proteins
DJ-1 and UCH-L1 were found to be covalently modified by dopamine (Van Laar et al.,
2009). This is consistent with evidence that dopamine quinone alters mitochondrial
function and induces swelling, effects which are inhibited by the addition of glutathione
(Berman and Hastings, 1999).

PD-associated parkin was found to be modified by

catechols in human SN, and modification of parkin by dopamine in neuronal cell lines
caused its functional inactivation (LaVoie et al., 2005). Dopamine quinone has also been
reported to covalently modify and inhibit the function of TH (Xu et al., 1998; Kuhn et al.,
1999) and DAT (Berman et al., 1996; Whitehead et al., 2001).
Toxin-based models of PD lend support for oxidative stress playing a role in
dopaminergic cell death. The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) induces parkinsonism via its active metabolite, 1-methyl-4-phenylpyridinium
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(MPP+) (Dauer and Przedborski, 2003), an effect which was first observed in drug users
who inadvertently synthesized MPTP (Davis et al., 1979; Langston et al., 1983).
Postmortem studies in these individuals as well as MPTP administration in monkeys and
mice has revealed nigrostriatal degeneration and depletion of striatal dopamine,
consistent with PD. Lewy body pathology has not been consistently observed, however
(Davis et al., 1979; Forno et al., 1993; Langston et al., 1999; Moratalla et al., 1992;
Muthane et al., 1994; Seniuk et al., 1990; Varastet et al., 1994). MPP+ is selectively
taken up by dopaminergic neurons through DAT (Javitch et al., 1985), and acts to inhibit
mitochondrial complex I activity (Nicklas et al., 1987). This can lead to production of
superoxide and other reactive oxygen species, and consequently oxidative stress
(Hasegawa et al., 1990; 1997). The insecticide rotenone also causes dopamine neuron
loss by inhibiting complex I (Betarbet et al., 2000), and the herbicide paraquat, which is
structurally related to MPP+, increases levels of superoxide (Day et al., 1999). Both
rotenone and paraquat are able to initiate formation of Lewy body-like α-synuclein
inclusions in rodents (Dauer and Przedborski, 2003). Furthermore, there is evidence for
increased risk of PD with herbicide/pesticide exposure (Tanner, 1992).

1.4.4 Animal models of dopamine toxicity
A limited number of studies have investigated whether dopamine is toxic in vivo.
Intrastriatal injection of high concentrations of dopamine (up to 1 μmol) in rats resulted
in loss of dopaminergic nerve terminals and formation of protein cysteinyl-dopamine
adducts within one week. The size of the lesion correlated with the concentration of
dopamine injected, and co-administration of glutathione or ascorbate both mitigated
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toxicity and decreased adduct formation (Filloux and Townsend, 1993; Hastings et al.,
1996; Rabinovic et al., 2000). Similarly, rats injected with aminochrome into the SN
showed evidence of neurodegeneration and motor impairment (Díaz-Véliz et al., 2002;
Touchette et al., 2016).
In addition to direct administration of dopamine or its oxidized derivatives,
pharmacological and genetic approaches have been taken to manipulate endogenous
dopamine handling and assess the effects on the nigrostriatal system. While a complete
knockout of VMAT2 is lethal (Wang et al., 1997), transgenic mice expressing 5% of
normal VMAT2 levels in order to increase cytosolic dopamine did not have SN cell loss
(Colebrooke et al., 2006). In a different strain of the same mice, a mild, progressive
degenerative phenotype was reported in combination with elevated levels of cysteinylcatechols (Caudle et al., 2007). Amphetamines are highly toxic to dopaminergic nerve
terminals, which is thought to be mediated at least in part by the redistribution of
dopamine from synaptic vesicles into the cytosol (Sulzer et al., 1995; LaVoie and
Hastings, 1999).

Mice deficient in VMAT2 exhibit greater sensitivity to meth-

amphetamine, consistent with exacerbated toxicity of cytosolic dopamine (Fumagalli et
al., 1999; Guillot et al., 2008). Conversely, overexpression of VMAT2 is protective
against methamphetamine-induced damage (Lohr et al., 2015).

Reserpine, another

inhibitor of vesicular dopamine storage, is not neurotoxic, possibly since its effects are
transient (Tieu, 2011). The elevation of cytosolic dopamine by overexpression of DAT
in SN neurons (Masoud et al., 2015) or ectopic DAT expression in striatal neurons (Chen
et al., 2008a) has resulted in neurodegeneration and oxidative stress. Collectively, these
studies emphasize the potential role of dopamine in PD etiology.
25

1.5 The interaction of dopamine and α-synuclein
1.5.1 Structural characterization
In 2001, Lansbury and colleagues conducted a screen for compounds that inhibit
α-synuclein fibrillization in vitro. Of the 15 candidates identified as potent modifiers of
aggregation, 14 were catecholamines. Dopamine was found to kinetically arrest soluble
α-synuclein oligomers, and this effect was blocked by antioxidants (Conway et al., 2001).
Subsequent studies have confirmed that dopamine stabilizes oligomer species in vitro
even at substoichiometric concentrations, and oxidation of dopamine but not α-synuclein
is required (Li et al., 2004; 2005a; Norris et al., 2005; Cappai et al., 2005; Follmer et al.,
2007; Herrera et al., 2008; Pham et al., 2009; Bisaglia et al., 2010; Mazzulli et al., 2016).
Consistent with these findings, elevating dopamine levels in SH-SY5Y cells expressing
A53T α-synuclein reduced the number of cells containing insoluble aggregates and
increased levels of soluble, high molecular weight oligomers. Moreover, the appearance
of these species was prevented by antioxidant treatment (Mazzulli et al., 2006; 2007).
The requirement of dopamine oxidation suggests that α-synuclein may interact
with dopamine quinones.

Indeed, aminochrome was found to effectively inhibit α-

synuclein fibril formation (Li et al., 2004; Norris et al., 2005), and incubation of
dopamine with α-synuclein results in quinone-associated protein (Li et al., 2005a;
Mazzulli et al., 2016). Interestingly, α-synuclein does not contain cysteine residues and
therefore cannot form cysteinyl adducts. Mutating other reactive residues that could
become covalently modified by dopamine does not have an effect, suggesting that the
interaction is non-covalent. Consistent with this, dopamine-mediated inhibition of αsynuclein fibrillization is reversible (Norris et al., 2005), and does not generate
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appreciable dopamine-protein adduct as measured by mass spectrometry and
radiolabeling (Li et al., 2004; Norris et al., 2005; Pham et al., 2009; Bisaglia et al., 2010).
The sites of interaction between dopamine and α-synuclein likely include residue E83
and the 125-YEMPS-129 motif in the C-terminus, since mutation or deletion of these
sites restores the ability of α-synuclein to fibrillize in the presence of dopamine (Norris et
al., 2005; Herrera et al., 2008). The dopamine-mediated increase in oligomeric species
observed in SH-SY5Y cells is also prevented by expression of α-synuclein lacking the
125-YEMPS-129 domain (Mazzulli et al., 2007).
Dopamine-stabilized α-synuclein oligomers have been extensively characterized
using a combination of biochemical and imaging techniques. Recombinant oligomers
generated in the presence of dopamine appear spherical or dot-like by electron
microscopy and atomic force microscopy, and both N- and C-termini of α-synuclein are
exposed (Cappai et al., 2005; Li et al., 2005a; Norris et al., 2005; Follmer et al., 2007).
These species migrate as high molecular weight bands on SDS-PAGE, indicating that
they are SDS- and heat-stable.

Further analysis by size exclusion chromatography

reveals a range of elution times, corresponding to heterogeneous oligomer conformations
(Conway et al., 2001; Cappai et al., 2005; Li et al., 2005a; Pham et al., 2009; Bisaglia et
al., 2010; Mazzulli et al., 2016). By circular dichroism, dopamine-incubated α-synuclein
is largely composed of random coil structure, consistent with ‘off-pathway’ species that
do not progress to form β-sheet rich fibrils (Li et al., 2004; Cappai et al., 2005; Norris et
al., 2005; Pham et al., 2009; Bisaglia et al., 2010). Collectively, these studies indicate
that oxidized dopamine potently modifies α-synuclein aggregation, resulting in diverse
soluble oligomeric conformers.
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1.5.2 Functional characterization
Growing evidence suggests that α-synuclein oligomers are neurotoxic species.
Viral expression of artificial α-synuclein variants with enhanced oligomerization in the
rat SN resulted in the selective loss of dopaminergic neurons (Winner et al., 2011).
Similarly, artificial mutants with impaired β-sheet structure and increased propensity to
form oligomers caused degeneration of dopaminergic nerve terminals when expressed in
worms and overt dopaminergic cell loss in flies (Karpinar et al., 2009). In another study,
oligomer extracts from A53T α-synuclein transgenic mice were found to be toxic when
applied to primary cortical cultures, while extracts immunodepleted of α-synuclein were
not (Tsika et al., 2010). Recombinant α-synuclein oligomers generated in vitro have also
been shown to be neurotoxic in culture (Danzer et al., 2007), and oligomer formation is
accelerated by the A53T and A30P familial PD mutations (Conway et al., 2000b).
Moreover, soluble high molecular weight oligomers have been extracted from human
brain tissue and are increased in PD patients (Sharon et al., 2003).
The toxicity of dopamine-induced α-synuclein oligomers is largely unexplored.
Evidence from neuronal cultures and cell-free assays suggests that these species are able
to inhibit their own degradation as well as that of other substrates by chaperone-mediated
autophagy (Martinez-Vicente et al., 2008). While there is no evidence that increasing
dopamine in SH-SY5Y cultures produces toxic α-synuclein oligomers (Mazzulli et al.,
2006; Yamakawa et al., 2010), exogenous application of recombinant dopaminestabilized oligomers has been reported to reduce viability and neurotransmitter release in
PC12 cells (Li et al., 2005a; Choi et al., 2013). A30P α-synuclein oligomers generated in
the presence of dopamine reduced neurite number
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and

length

in

primary

mesencephalic and cortical cultures (Follmer et al., 2007). In addition, the toxicity of
endogenous cytosolic dopamine in cultured fetal human dopaminergic neurons was
linked to the accumulation of soluble α-synuclein protein complexes (Xu et al., 2002).

1.6 Rationale and objectives
A major stumbling block in the development of effective treatments for PD has
been the inadequate understanding of two defining disease features: the progressive death
of dopaminergic neurons in the SN, and the widespread formation of α-synuclein
inclusions. A longstanding hypothesis suggests that dopamine contributes to disease
pathogenesis through the generation of cytotoxic quinones and other electrophiles
(Graham, 1978), yet dopamine toxicity has not been extensively studied in animal
models. Oxidized dopamine has been shown to stabilize potentially toxic α-synuclein
oligomers in cultured cells and cell-free systems (Conway et al., 2001; Norris et al., 2005;
Mazzulli et al., 2006; 2007). However, it remains unknown if dopamine is able to
modify α-synuclein oligomerization in vivo and whether the resultant species are capable
of driving neurodegeneration.
To explore the possibility that dopamine and α-synuclein interact in vivo, we
manipulated both endogenous dopamine levels and α-synuclein expression in mice
(Chapter 2). Using A53T human α-synuclein transgenic mice (Giasson et al., 2002) and a
novel lentiviral approach to enhance dopamine synthesis, we aimed to accomplish three
major goals: (1) to test if sustained elevation of dopamine levels induces nigrostriatal
degeneration, (2) to determine if dopamine toxicity is dependent on α-synuclein
expression, and (3) to test if dopamine modifies α-synuclein aggregation in vivo
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resulting in potentially toxic species. We found that both elevated dopamine levels and
α-synuclein expression are required for neurodegeneration of the SN, and that dopamine
promotes conformationally and functionally modified α-synuclein oligomer species in
vivo. In addition, we found that dopamine-stabilized recombinant α-synuclein oligomers
are structurally similar to mouse-derived oligomers and are toxic to primary neuronal
cultures.

These findings reveal a synergistic interaction between dopamine and α-

synuclein that may account for the vulnerability of dopaminergic neurons in disease.
In Chapter 3, we review what is known regarding α-synuclein physiological
functions and native conformations. A model for the transition from native α-synuclein
conformers to aggregation-competent species is proposed.
Finally, Chapter 4 provides a summary of our findings, their significance within
the broader scientific understanding, and clinical implications. Important questions that
remain following this work, as well as future studies that may address these questions, are
highlighted.
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2.1 Abstract
Parkinson’s disease is defined by the loss of dopamine producing neurons in the
substantia nigra (SN) and an abundance of Lewy body inclusions comprised of
aggregated α-synuclein.

To date, efforts to explain the selective vulnerability of

dopamine neurons have been hindered by the lack of overt dopaminergic cell death in
transgenic mice overexpressing α-synuclein. To address this issue, dopamine levels were
manipulated in addition to α-synuclein expression, since the oxidative properties of
dopamine have long been suspected to contribute to dopaminergic cell death.

SN-

targeted expression of mutant tyrosine hydroxylase, which is insensitive to feedback
inhibition by dopamine, increased the steady-state levels of dopamine without damaging
dopaminergic cells in non-transgenic mice. In contrast, raising dopamine levels in mice
expressing human A53T mutant α-synuclein induced progressive nigrostriatal
degeneration and a reduction of locomotion. A possible mechanism for this converging
action is dopamine-mediated stabilization of α-synuclein oligomers, which occurs in cellfree and culture systems but has not been tested in vivo. Elevation of dopamine in A53T
transgenic mice increased the total levels of soluble α-synuclein oligomers and resulted in
conformationally and functionally modified species.

Moreover, dopamine-induced

α-synuclein oligomers generated in vitro decreased viability in primary neuronal cultures.
The data demonstrate that SN degeneration is dependent on both dopamine levels and
α-synuclein, suggesting a unique interaction by which two cardinal features of
Parkinson’s disease, dopaminergic cell death and α-synuclein aggregation, are linked to
account for the vulnerability of this neuronal population.
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2.2 Introduction
Parkinson’s disease (PD) is a debilitating neurodegenerative disorder that is
principally defined by the motor symptoms of resting tremor, rigidity, and bradykinesia.
These symptoms occur primarily as a result of the progressive loss of dopaminergic
neurons in the substantia nigra pars compacta (SN), which depletes dopamine at
nigrostriatal synapses (Parkinson, 1817; Hassler, 1938; Ehringer and Hornykiewicz,
1960). A longstanding hypothesis to explain the vulnerability of this cell population
states that dopamine induces neuronal injury via oxidative stress. The enzyme- or metalcatalyzed oxidation of dopamine generates electron-deficient quinones and reactive
oxygen species that can induce cellular dysfunction (Graham, 1978; Fahn and Cohen,
1992; Jenner and Olanow, 1996; Stokes et al., 1999). The SN in PD patients is reported
to harbor oxidatively modified proteins, lipids, and nucleic acids (Dexter et al., 1989a;
Yoritaka et al., 1996; Zhang et al., 1999; Giasson et al., 2000). Efforts to study the
effects of dysregulated dopamine in animal models have included ectopic dopamine
administration or increased cytosolic dopamine by suppression of VMAT2 expression
(Hastings et al., 1996; Colebrooke et al., 2006; Caudle et al., 2007).
More recently, α-synuclein has emerged as a critical player in PD pathogenesis.
Disturbances in α-synuclein protein folding or expression level, i.e. through mutations or
extra copies of the α-synuclein gene, are known causes of PD (Polymeropoulos et al.,
1997; Krüger et al., 1998; Singleton et al., 2003; Chartier-Harlin et al., 2004; Zarranz et
al., 2004; Proukakis et al., 2013; Lesage et al., 2013; Pasanen et al., 2014; Ferese et al.
2015). In both familial and sporadic cases, aggregated α-synuclein is present within
Lewy bodies and Lewy neurites, which are the hallmark pathological lesions of the
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disease (Spillantini et al., 1997; Baba et al., 1998).

α-Synuclein is a small highly

conserved protein (140 residues) that is abundantly expressed in the nervous system
primarily at presynaptic terminals (Maroteaux et al., 1988; Jakes et al., 1994; Iwai et al.,
1995). The precise physiological functions of α-synuclein remain unclear, though it is
thought to play diverse roles in synaptic maintenance and plasticity, neurotransmitter
release and homeostasis, and the regulation of synaptic vesicle pools (George et al., 1995;
Withers et al., 1997; Abeliovich et al., 2000; Murphy et al., 2000; Cabin et al., 2002;
Yavich et al., 2004; Chandra et al., 2005; Burré et al., 2010; Nemani et al., 2010). In
disease, α-synuclein assembles into β-sheet rich amyloid-like fibrils, generating several
intermediate oligomeric species of unknown toxicity (Ross and Poirier, 2005).
Intriguingly, α-synuclein oligomers are kinetically stabilized by oxidized
dopamine and other catecholamines in vitro (Conway et al., 2001; Norris et al., 2005),
providing a possible link between dopamine- and α-synuclein-mediated toxicities.
Extensive evidence from cultured cells and cell-free systems indicates that dopamine
potently and substoichiometrically inhibits the fibrillization of α-synuclein, resulting in
the kinetic arrest of soluble oligomer species.

Dopamine oxidation is required for

oligomer stabilization, suggesting α-synuclein interacts with dopamine-quinone and/or
other oxidation products. The interaction is non-covalent, reversible, and dependent on
residues E83 and 125-YEMPS-129 motif in the C-terminus of α-synuclein (Conway et
al., 2001; Norris et al., 2005; Cappai et al., 2005; Mazzulli et al., 2006; 2007; Follmer et
al., 2007; Herrera et al., 2008). The toxicity of these oligomers is largely unexplored,
though in vitro dopamine-incubated α-synuclein is reported to interfere with and resist
degradation

by

chaperone-mediated autophagy
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(Martinez-Vicente

et

al.,

2008), and to inhibit SNARE complex formation and neurotransmitter release (Choi et
al., 2013).

Importantly, it is unknown if dopamine is able to modify α-synuclein

oligomerization

in vivo and whether the resultant species are capable of driving

neurodegeneration. These are the critical questions we aimed to answer in this study.

2.3 Results
2.3.1 Expression of TH-RREE elevates dopamine levels and causes hyperactivity in
NonTg mice
To increase dopamine levels in vivo, we used a lentiviral vector carrying the
cDNA of human tyrosine hydroxylase (TH). TH is the rate-limiting enzyme in dopamine
biosynthesis converting tyrosine to L-DOPA, which is then metabolized by aromatic
amino acid decarboxylase to generate dopamine. A mutated TH enzyme that has Arg37Arg38 replaced by Glu37-Glu38 (TH-RREE) is insensitive to feedback inhibition by
dopamine and was used to achieve increased catalytic activity of TH (Nakashima et al.,
2002; Mazzulli et al., 2006; 2007). The function of the vector was first tested on human
neuroblastoma SH-SY5Y cells. This cell line has undetectable levels of endogenous TH,
despite the expression of other enzymes required for synthesis and processing of
dopamine. The cells were transduced after 5 days of differentiation with 20 µM retinoic
acid and TH expression was confirmed by western blot and immunocytochemistry
compared with empty vector (CtrlVect)-transduced controls (Figure 2.S1a-c).

The

TH-RREE transduced cells had measurable intracellular levels of L-DOPA, dopamine,
and DOPAC in the range of 25-200 fm/μg, whereas catecholamines were not detected in
CtrlVect-transduced cells (Figure 2.S1d).
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We performed bilateral injections of TH-RREE vector into the SN of aged (10
month old) NonTg mice. This age was selected because the mice expressing A53T
mutant human α-synuclein are asymptomatic and do not exhibit the well-known motor
phenotype derived from spinal cord degeneration (Giasson et al., 2002). The typical age
of onset of this phenotype in our colony is approximately 18 months. At 5 months postinjection (mpi), TH expression was increased in both SN and striatum in NonTg
TH-RREE mice compared to age-matched NonTg CtrlVect mice (Figure 2.1a-b).

Figure 2.1: Increased dopamine levels in the striatum of NonTg mice results in
hyperactivity. (a) TH protein levels were increased in the striatum of TH-RREE vector injected
mice relative to empty vector-injected controls (CtrlVect) at 5 mpi. Densitometric analysis was
conducted by normalizing TH to the GAPDH loading control. The data are presented as mean ±
s.e.m. (n = 3; two-tailed unpaired Student’s t test). (b) Increased TH expression was confirmed
by immunohistochemistry in the SN (left panels) and striatum (right panels). Scale bar, 200 μm.
(c) TH overexpression significantly increased the steady state concentrations of striatal
catecholamines L-DOPA and dopamine (DA), but did not alter DOPAC or 5-HT. The data are
presented as mean ± s.e.m. (n = 4 except DOPAC n = 5 for CtrlVect, and 5-HT n =3 for THRREE; two-tailed unpaired Student’s t test). (d) TH-RREE injected NonTg mice exhibited
greater locomotion as measured by open field activity. The data are presented as mean ± s.e.m.
(n = 5; two-tailed unpaired Student’s t test). (e) There was no change in rotarod performance
between the injection groups. The data are presented as mean ± s.e.m. (n = 3; two-tailed
unpaired Student’s t test). *P < 0.05.
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TH-RREE significantly elevated striatal concentrations of L-DOPA and dopamine by 36
and 52%, respectively, while DOPAC was not affected. Importantly, 5-HT levels did not
change, indicating a specific effect on the catecholamine neurotransmitter system (Figure
2.1c). Consistent with elevated striatal dopamine, NonTg TH-RREE mice exhibited
hyperactivity in open field testing compared with NonTg CtrlVect mice (Figure 2.1d).
There was no difference in rotarod performance between the NonTg injection groups
(Figure 2.1e). These data indicate that the TH-RREE vector is able to significantly
enhance dopamine levels fully 5 months following injection.

2.3.2 Dopamine-induced neurodegeneration and motor deficit is dependent on
α-synuclein expression
Bilateral injection of the TH-RREE vector into the SN of 10 month old A53T
mutant α-synuclein mice also achieved TH overexpression (Figure 2.S2). However, in
contrast to NonTg mice, A53T TH-RREE mice exhibited striatal degeneration and
neuronal loss in the SN at 5 mpi. To avoid the detection of vector-encoded TH, we used
another marker of dopaminergic neurons, VMAT2, to evaluate neuronal loss. A53T
TH-RREE mice had fewer VMAT2 positive cells in the SN compared with all other
injection groups (Figure 2.2a).

We quantified the loss of neurons using unbiased

stereological counting of Nissl cells, which revealed a significant 25% reduction in A53T
TH-RREE mice compared to controls (Figure 2.2b). The number of neurons quantified
in age-matched A53T CtrlVect as well as NonTg CtrlVect and NonTg TH-RREE mice
was typical for the mouse SN (Tieu et al., 2003), indicating that neurodegeneration had
not occurred in these mice (Figure 2.2b).
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Figure 2.2: Dopamine-induced neurodegeneration of the SN is dependent on α-synuclein.
(a) At 5 mpi, fewer VMAT2 positive cells were present in the SN of A53T TH-RREE mice
(arrows) compared with all other injection groups. Scale bar, 100 μm. (b) Unbiased stereological
counting of Nissl-positive neurons in the SN revealed a significant 25% loss of cells in A53T THRREE mice. The data are presented as mean ± s.e.m. (n = 3 except n = 4 for A53T TH-RREE;
one-way ANOVA with Tukey’s correction for multiple comparisons). (c-d) Histological analysis
of VMAT2 staining in the striatum, with subtraction of background staining in the cortex,
indicated severe dopaminergic denervation in A53T TH-RREE mice. Scale bar, 200 μm. The
data are presented as mean ± s.e.m. (n = 3; one-way ANOVA with Tukey’s correction for
multiple comparisons). (e-f) Striatal DAT levels normalized to the actin loading control were
increased in NonTg TH-RREE mice relative to NonTg CtrlVect, whereas DAT levels were
decreased in A53T TH-RREE mice as compared to A53T CtrlVect. The data are presented as
mean ± s.e.m. (n = 3 except n = 4 for NonTg CtrlVect; one-way ANOVA with Tukey’s
correction for multiple comparisons). *P < 0.05, **P < 0.01.

The degeneration of cell bodies was accompanied by a significant 62% decrease
in VMAT2 staining in the striatum of A53T TH-RREE mice, demonstrating a severe loss
of dopaminergic nerve terminals (Figure 2.2c-d). Denervation of the striatum was further
corroborated by quantification of DAT levels, which revealed a significant 55% decline
in A53T TH-RREE mice compared with A53T CtrlVect. In contrast, DAT levels
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were two-fold higher in NonTg TH-RREE as compared to NonTg CtrlVect mice (Figure
2.2e-f). DAT upregulation may serve to compensate for increased dopamine levels, and
may not be apparent in A53T TH-RREE mice due to the substantial loss of dopaminergic
terminals. The injury in A53T mice appears to be primarily presynaptic in that levels of
D1 and D2 receptors remained unchanged (Figure 2.S3a-c). Levels of dopamine- and
cAMP-regulated phosphoprotein-32 (DARPP-32), which serves as an important signaling
molecule in spiny projection neurons, were also unaffected (Figure 2.S3a,d).
To further investigate the degenerative phenotype in A53T TH-RREE mice and
whether it is progressive, the total number of SN neurons was quantified at the earlier
timepoint of 2.5 mpi. No difference was observed between A53T CtrlVect and THRREE mice, indicating that cell loss had not yet occurred (Figure 2.3a). Despite the
maintenace of neuronal cell bodies, striatal VMAT2 levels revealed a 25% decrease in
nerve terminal density by this timepoint, suggesting that degeneration had begun at
dopaminergic synapses (Figure 2.3b). DAT levels were instead found to be increased in
A53T TH-RREE mice relative to CtrlVect mice at 2.5 mpi (Figure 2.3c), similar to
NonTg TH-RREE mice at 5 mpi (Figure 2.2e-f).

Consistent with a compensatory

increase in DAT, dopamine levels at 2.5 mpi were significantly elevated by 71% in A53T
TH-RREE mice compared with age-matched A53T CtrlVect mice (Figure 2.3d).
Following the initial increase in dopamine, however, A53T TH-RREE mice
subsequently exhibited a 37% drop in striatal dopamine content between 2.5 and 5 mpi.
A53T CtrlVect mice showed no change in dopamine during the same time period (Figure
2.3d). The reduction in dopamine levels cannot be explained by increased conversion to
DOPAC since

levels of this metabolite remained unchanged from 2.5 to 5 mpi
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Figure 2.3: Development of the neurodegenerative phenotype in A53T TH-RREE mice
ultimately leading to locomotor deficit. (a) At the early timepoint of 2.5 mpi, A53T TH-RREE
mice did not yet exhibit loss of neuronal cell bodies in the SN. The data are presented as mean ±
s.e.m. (n = 4 except n = 3 for TH-RREE; two-tailed unpaired Student’s t test). (b) VMAT2
staining in the striatum revealed a modest loss of terminals suggesting that dopaminergic
synapses had degenerated prior to overt cell death. Scale bar, 200 μm. The data are presented as
mean ± s.e.m. (n = 4; two-tailed unpaired Student’s t test). (c) DAT levels in the striatum of
A53T TH-RREE mice were instead found to be increased at 2.5 mpi. The data are presented as
mean ± s.e.m. (n = 3; two-tailed unpaired Student’s t test). (d) A53T TH-RREE mice exhibited
an elevation of dopamine (DA) levels only transiently, with an initial increase of 71% at 2.5 mpi
compared with age-matched A53T CtrlVect mice. Subsequently, however, A53T TH-RREE
mice underwent a significant 37% drop in striatal dopamine between 2.5 and 5 mpi, which was
not observed in A53T CtrlVect mice. The data are presented as mean ± s.e.m. (n = 3 except n =
5 for TH-RREE 2.5 mpi; one-way ANOVA with Tukey’s correction for multiple comparisons).
(e) Consistent with a late-onset depletion of dopamine in the striatum, from 2.5 to 5 mpi A53T
TH-RREE mice developed a reduction in locomotor activity that was not observed in CtrlVect
mice. The data are presented as mean ± s.e.m. (n = 3; one-way ANOVA with Tukey’s correction
for multiple comparisons). (f) The motor deficit in A53T TH-RREE mice was not severe enough
to affect coordination or balance, as rotarod performance remained intact. The data are presented
as mean ± s.e.m. (n = 4 except n = 3 for TH-RREE 2.5 mpi and CtrlVect 5 mpi; one-way
ANOVA with Tukey’s correction for multiple comparisons). *P < 0.05, **P < 0.01.
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(Figure 2.S4a). We also did not detect an increase in dopamine-protein adducts by near
infrared fluorescence (Figure 2.S4b-c). Rather, the loss of dopamine is likely due to the
ongoing nigrostriatal degeneration documented in these mice. Concomitant with the
decrease in dopamine levels, A53T TH-RREE mice exhibited a significant impairment in
ambulatory activity that was not apparent at 2.5 mpi but emerged by 5 mpi (Figure 2.3e).
Performance on the rotarod remained intact, suggesting that balance and coordination
were not disrupted (Figure 2.3f). Collectively, the results show that dopamine promotes
the progressive neurodegeneration of dopaminergic neurons and a specific motor deficit
in mice that express A53T α-synuclein, but not in NonTg mice.

2.3.3 Dopamine modifies α-synuclein oligomer conformations in A53T mice
The data indicate that increased steady state levels of dopamine result in
neurotoxicity in an α-synuclein dependent manner. To investigate possible mechanisms,
we examined the influence of dopamine on α-synuclein aggregation, and in particular the
kinetic stabilization of potentially toxic α-synuclein oligomers. The presence of Lewy
body-like inclusions in circumscribed regions including the brainstem of aged A53T mice
has been well documented (Giasson et al., 2002). α-Synuclein-positive inclusions were
indeed detected in the brainstem of A53T TH-RREE mice at 5 mpi (age 15 months),
similar to age-matched A53T CtrlVect mice (Figure 2.S5a). In contrast, the SN is known
to remain devoid of inclusions during the lifespan of A53T mice (Giasson et al., 2002).
Expression of TH-RREE vector did not induce α-synuclein inclusion formation or alter
levels of detergent-insoluble α-synuclein in the SN at 5 mpi (Figure 2.S5).
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Examination of detergent-soluble α-synuclein extracted from SN of A53T mice at
5 mpi revealed significant alterations in the quantities and conformations of α-synuclein
species as a result of dopamine elevation. A53T TH-RREE mice had a significant 22%
reduction in monomeric human α-synuclein compared with A53T CtrlVect mice (Figure
2.4a-b).

Upon fractionation of the soluble SN extract by native size exclusion

chromatography (SEC), we detected the presence of various oligomeric α-synuclein
species of different molecular weights (Figure 2.4c). Quantification of total oligomeric
species revealed a significant increase in A53T TH-RREE mice, greater than two-fold
above A53T CtrlVect mice (Figure 2.4d).

To characterize the oligomers, we used

multiple α-synuclein antibodies and a combination of SDS-PAGE, immunoelectron
microscopy, and biochemical assays. In A53T CtrlVect mice, oligomers had Stokes radii
of up to 65 Å and ranged in molecular weight from 36 to 80 kD (Figure 2.4c and Figure
2.S6a-b), consistent with previous observation (Tsika et al., 2010). However, in addition
to these low Å species, larger species of up to 122 Å were detected in A53T TH-RREE
mice.

On 12% SDS-PAGE, these species migrated as dimers, trimers, and high

molecular weight polymers stable to SDS and heat, consistent with the presence of
oxidized/crosslinked species (Souza et al., 2000). The appearance of unique, high Å
species in A53T TH-RREE mice was observed with multiple α-synuclein antibodies that
recognize N- or C-terminal epitopes (Figure 2.4c and Figure 2.S6a-b).

Moreover,

analysis of quinone-associated protein by near-infrared fluorescence revealed that only
the high Å oligomeric fractions from A53T TH-RREE mice were positive, supporting a
direct interaction of dopamine and α-synuclein oligomers in these mice (Figure 2.S6c).
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Figure 2.4: Dopamine induces conformationally distinct α-synuclein oligomers in vivo. (a-d)
The SN of A53T TH-RREE and A53T CtrlVect mice at 5 mpi was extracted with 1% Triton and
the soluble fraction was analyzed by SDS-PAGE (a-b). The soluble extract was further subjected
to native size exclusion chromatography and fractions corresponding to 31-38 Å, 41-65 Å, and
72-122 Å were pooled and analyzed by SDS-PAGE (c-d). Neural specific enolase (NSE) was
used as a loading control. The quantification revealed a decrease in soluble α-synuclein monomer
and a corresponding increase in α-synuclein oligomers in A53T TH-RREE compared with A53T
CtrlVect. The oligomer species in A53T TH-RREE mice were present in higher Å fractions than
in controls and had a range of molecular weights. The data are presented as mean ± s.e.m.
(Monomer, n = 3 for CtrlVect and n = 5 for TH-RREE; Oligomer, n = 3 for CtrlVect and n = 4
for TH-RREE; two-tailed unpaired Student’s t test). (e) Immunoelectron microscopy on low (4165) and high (72-122) Å fractions using Syn505 (N-terminal) and LB509 (C-terminal) αsynuclein antibodies, with 10 nm gold-conjugated secondary. Scale bar, 10 nm. (f) Pooled
oligomeric fractions (41-122 Å) from indicated mice were added to aggregation reactions with
fresh recombinant α-synuclein, and fibril formation was monitored by Thioflavin T (ThioT).
Prior immunodepletion of α-synuclein from A53T CtrlVect fractions was performed as a control.
rfu, relative fluorescence units. The data are presented as mean ± s.e.m. (n = 3 except n = 4 for
no seed and immunodepl; repeated measures two-way ANOVA with Tukey’s correction for
multiple comparisons). *P < 0.05, **P < 0.01.
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Further structural analysis of oligomers isolated from high (72-122) or low (4165) Å SEC fractions was done by immunoelectron microscopy. Oligomers typically
appeared as clusters with >2 gold particles in both high and low Å fractions from A53T
TH-RREE mice as well as low Å fractions from A53T CtrlVect mice. The species were
labeled with α-synuclein antibodies directed at either the N- or C-terminus, indicating
that both ends were exposed (Figure 2.4e). Clusters of >2 gold particles were not
observed in high Å fractions from A53T CtrlVect mice or fractions from A53T THRREE mice that were immunodepleted of α-synuclein prior to imaging.
Since there is growing evidence for prion-like spreading of α-synuclein pathology
in disease (Goedert et al., 2010), we investigated if dopamine promotes oligomeric
species with the capacity to propagate in vivo. α-Synuclein oligomers extracted from
A53T TH-RREE and A53T CtrlVect mice (pooled 41-122 Å SEC fractions) were
monitored in a seeding assay with fresh recombinant α-synuclein in vitro. In the case of
CtrlVect mice, oligomers efficiently seeded aggregation relative to the no-seed condition,
as measured by Thioflavin T (Figure 2.4f). Importantly, this effect was abolished by
prior immunodepletion of α-synuclein from the SEC fractions. In contrast, the same
fractions from TH-RREE mice were unable to act as seeds (Figure 2.4f), suggesting that
seeding-competent species were not retained following the interaction of α-synuclein
with dopamine in vivo. Collectively, these data indicate that dopamine promotes the
generation of conformationally and functionally modified α-synuclein oligomeric species
in the mouse brain.
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2.3.4 Dopamine-induced α-synuclein oligomers are neurotoxic in primary cultures
To further establish the link between dopamine-induced oligomers and toxicity,
we used purified recombinant human wildtype α-synuclein co-incubated with dopamine
in vitro. Consistent with prior reports (Conway et al., 2001; Norris et al., 2005; Cappai
et al., 2005; Follmer et al., 2007), analysis of amyloid formation with Thioflavin T
indicated that at equimolar concentrations, dopamine potently inhibited α-synuclein
fibrillization (Figure 2.5a). In the absence of dopamine, α-synuclein adopted typical βsheet structure indicative of amyloid formation, whereas under conditions with dopamine,
α-synuclein retained random coil structure (Figure 2.5b).

Sedimentation analysis

confirmed that dopamine promotes soluble α-synuclein oligomer species that are SDSand heat-stable (Figure 2.5c). Similar to mouse-derived oligomers, recombinant species
ranged from 36 to >98 kD and were recognized by both N- and C-terminally directed αsynuclein antibodies in western blots and by immunoelectron microscopy (Figure 2.5c-d).
Imaging by electron microscopy revealed clusters of >2 gold particles as observed in
oligomer fractions from mouse SN (Figure 2.5d and Figure 2.4e). These findings suggest
that dopamine-induced oligomers generated in vitro share common epitopes and
potentially similar conformations to oligomers resulting from dopamine elevation in vivo.
The toxicity of recombinant oligomers was tested using primary mouse neuronal
cultures. Hippocampal neurons were cultured for one week prior to treatment with the
products of α-synuclein incubation with dopamine or control treatments. Two weeks
post-treatment, exogenous α-synuclein from oligomer preparations had become
internalized within neurons and localized to neurites (Figure 2.6a). At this timepoint, cell
viability was evaluated using Calcein AM and propidium iodide (PI) dyes.
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Figure 2.5: Biochemical and structural characterization of α-synuclein oligomers resulting
from incubation with dopamine in vitro. (a) Incubation of recombinant wildtype human αsynuclein under standard aggregation conditions (400 μM, 37°C, 1400 rpm) resulted in
Thioflavin T (ThioT)-positive fibril formation, whereas ThioT signal was abolished in the
presence of equimolar dopamine (DA). rfu, relative fluorescence units. The data are presented as
mean ± s.e.m. (n = 3; repeated measures two-way ANOVA with Bonferroni’s correction for
multiple comparisons). (b) α-Synuclein fibrils exhibited characteristic β-sheet secondary
structure by circular dichroism, while α-synuclein species resulting from interaction with
dopamine maintained random coil structure on day 5 of incubation. Representative traces are
shown. (c) Sedimentation analysis and coomassie blue staining revealed that over the 6-day
incubation, in the absence of dopamine, soluble α-synuclein (supernatant) was lost while
insoluble α-synuclein (pellet) accumulated. In the presence of dopamine, α-synuclein did not
become insoluble but instead was detected as multiple soluble oligomer species. Similar to ex
vivo oligomers extracted from A53T TH-RREE mice, in vitro generated oligomers were
immunoreactive to Syn505 (N-terminal) and LB509 (C-terminal) α-synuclein antibodies. (d)
Immunoelectron microscopy on α-synuclein from day 4 of incubation with dopamine confirmed
both Syn505 and LB509 labeling. Scale bar, 20 nm. **P < 0.01.
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Figure 2.6: α-Synuclein oligomers
generated in vitro in the presence of
dopamine become internalized and are
toxic to primary neurons. Hippocampal
neurons at 7 days in vitro were exposed to
0.5 or 1 μM α-synuclein oligomer that had
been prepared in the presence of dopamine
(Olig), or 1 μM monomer (Mon), 1 μM
dopamine that was incubated in parallel to
oligomers but without α-synuclein (DA), or
an equivalent dose of PBS. (a) Two weeks
post-treatment with 1 μM Olig or PBS, cells
were labeled with human α-synuclein
antibodies in a two-stage protocol. Cells
were live-incubated with Syn204 antibody
to label extracellular α-synuclein. Following
fixation and permeabilization, the cells were
incubated with LB509 to label total αsynuclein.
Confocal imaging showed
puncta that were labeled by LB509 but not
Syn204,
indicating
that
exogenous
oligomers had been internalized. These
puncta were localized to neurites. Scale bar,
10 μm. (n = 3). (b-c) At two weeks posttreatments, cell viability was assayed using
Calcein AM and propidium iodide (PI)
dyes. The number of viable cells, defined as
Calcein AM positive and PI negative, was
significantly reduced by exposure to 1 μM
Olig but was not affected by Mon or DA
controls. Treatment with 0.5 μM Olig was
insufficient to induce toxicity, indicating
that the effect is dependent on dose. Scale
bar, 100 μm. The data are presented as
mean ± s.e.m. (n = 4 except n = 3 for PBS
and DA, and n = 5 for 1 μM Olig; one-way
ANOVA with Tukey’s correction for
multiple comparisons). *P < 0.05, **P <
0.01.
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Exposure of neurons to 1 μM dopamine-incubated α-synuclein induced a significant 44%
reduction in Calcein positive-PI negative cells relative to PBS treated controls (Figure
2.6b-c). Treatment with equivalent doses of monomeric α-synuclein, or dopamine that
had been incubated under aggregation conditions but without α-synuclein, did not reduce
cell viability (Figure 2.6b-c). The observed neurotoxicity can therefore be attributed
specifically to α-synuclein oligomers, consistent with our findings in vivo linking
dopamine-modified species with severe nigrostriatal degeneration.

2.4 Discussion
In this study we used a novel lentiviral vector approach to enhance dopamine
levels specifically in the SN of transgenic mice expressing the human A53T familial PD
mutant of α-synuclein. In this well-characterized mouse model, the SN does not develop
α-synuclein inclusions and does not undergo neuronal cell loss (Giasson et al., 2002).
However, elevation of dopamine induced significant nigrostriatal degeneration and a
previously undescribed ambulatory phenotype in A53T mice. Neurodegeneration of the
SN was not observed in NonTg mice receiving the same treatment, indicating that
dopamine-induced toxicity is dependent on α-synuclein expression. Furthermore, we
demonstrate for the first time in vivo, dopamine-mediated changes in the total levels of
α-synuclein oligomers as well as their biochemical and functional properties, suggesting
that disrupting this interaction may be a promising new target in PD treatment.
Dopamine has long been considered a contributor to the death of dopaminergic
neurons in disease (Fahn and Cohen, 1992; Jenner and Olanow, 1996; Stokes et al.,
1999).

The acidic conditions within synaptic
48

vesicles

serve

to

maintain

dopamine in a reduced state. However, at physiological pH in the cytosol, dopamine
readily auto-oxidizes to form reactive quinone species, hydrogen peroxide, and other
electrophiles (Graham, 1978). Despite the importance of understanding mechanisms of
dopamine neurotoxicity, few studies have examined the role of dopamine in SN
neurodegeneration in vivo. Intrastriatal injection of dopamine in rats resulted in proteinbound catechols and injury to dopaminergic nerve terminals after seven days. The size of
the lesion was correlated with increasing concentrations of dopamine, and was
diminished by co-administration with glutathione or ascorbate indicating that oxidation of
dopamine was responsible for the injury (Hastings et al., 1996).

Transgenic mice

expressing 5% of normal VMAT2 levels had an age-dependent decline in striatal
dopamine that was accompanied by decreased rotarod performance without degeneration
of the SN (Colebrooke et al., 2006). In the same transgenic mice, a mild progressive
nigrostriatal degeneration in aged mice was reported (Caudle et al., 2007). These studies
indicate that cytosolic dopamine could be toxic, but the long-term effects of raising
nigrostriatal dopamine levels has remained unknown.
The present study provides the first investigation of dopamine toxicity by chronic
enhancement of dopamine synthesis in vivo. By expressing a mutant TH enzyme lacking
residues that are critical for feedback inhibition by dopamine (Nakashima et al., 2002;
Mazzulli et al., 2006; 2007), striatal dopamine in NonTg mice was increased by over
50%.

Surprisingly, this significant perturbation of dopamine homeostasis was

insufficient to induce SN degeneration. NonTg TH-RREE mice maintained a normal
number of neurons in the SN, intact synaptic contacts with the striatum, and robust motor
coordination/balance.

The fate of excess dopamine in these animals is likely
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release into the synapse, leading to the observed increase in locomotion.

This is

consistent with other studies in which increased extracellular dopamine in the striatum
resulted in hyperactivity (Zhuang et al., 2001; Lohr et al., 2014). Dopamine can therefore
be well-tolerated in the absence of an additional burden or defect.
α-Synuclein has been independently linked to PD through the discovery of
dominantly inherited mutations and multiplications of the SNCA gene (Polymeropoulos et
al., 1997; Krüger et al., 1998; Singleton et al., 2003; Chartier-Harlin et al., 2004; Zarranz
et al., 2004; Proukakis et al., 2013; Lesage et al., 2013; Pasanen et al., 2014; Ferese et al.
2015). In non-familial PD, which accounts for roughly 90% of cases, aggregated wild
type α-synuclein is present in Lewy body and Lewy neurite inclusions (Spillantini et al.,
1997; Baba et al., 1998).

Efforts to model PD by transgenic overexpression of

α-synuclein in mice have yielded mixed results. Expression of wild type α-synuclein
under the PDGF-β promoter resulted in atypical non-fibrillar α-synuclein inclusions and
reduced TH immunoreactivity in the striatum without overt dopaminergic cell loss
(Masliah et al., 2000). In mice expressing human wild type or familial mutants (A30P,
E46K, or A53T) of α-synuclein under the PrP promoter, the SN was consistently spared
of both neurodegeneration and α-synuclein inclusion pathology, despite the development
of Lewy body-like inclusions in other regions specifically in A53T transgenic mice
(Giasson et al., 2002; Lee et al., 2002; Gispert et al., 2003; Gomez-Isla et al., 2003;
Yavich et al., 2005; Martin et al., 2006; Emmer et al., 2011.) Similarly, Thy1-driven
expression of human A30P α-synuclein did not result in histopathological changes or
neuron loss in the SN, possibly due to low levels of transgene expression (RathkeHartlieb et al., 2001; Neumann et al., 2002). Targeting wild type, A30P, or A53T
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human α-synuclein expression specifically to dopaminergic neurons using the TH
promoter was insufficient to produce either nigrostriatal degeneration or Lewy body-like
α-synuclein pathology (Rathke-Hartlieb et al., 2001; Matsuoka et al., 2001; Richfield et
al., 2002).

Greater success inducing dopaminergic cell death was achieved using

bacterial artificial chromosome transgenic mice expressing human wild type α-synuclein
(Janezic et al., 2013) or by conditional expression of human wild type or A53T αsynuclein (Nuber et al., 2008; Lin et al., 2012). In our study, we used transgenic mice
with PrP-driven expression of A53T α-synuclein (Giasson et al., 2002). In late age, these
mice have a documented increase in basal dopamine levels in the striatum relative to
NonTg mice (Tsika et al., 2010), which is consistent with our quantification of both
catecholamines and DAT levels. However, degeneration of the SN does not occur in
A53T mice without further enhancement of dopamine levels by TH-RREE expression.
In stark contrast to NonTg mice, elevation of dopamine levels in A53T mice
resulted in previously undescribed, progressive nigrostriatal degeneration with a
locomotor impairment, markedly improving this mouse as a model of PD. Within 2.5
months after TH-RREE vector injection into A53T mice, dopaminergic innervation to the
striatum assessed by VMAT2 had decreased by 25%, while cell bodies in the SN
remained intact. By 5 mpi, denervation had progressed to 62% loss of VMAT2-positive
fibers with corresponding decrease in DAT, and a significant loss of neurons had
occurred. These degenerative changes coincided with a reduction of dopamine levels in
the striatum, and the development of a hypoactive phenotype.

Notably, the initial

increase in dopamine in A53T TH-RREE mice at 2.5 mpi was not accompanied by
hyperactivity, as observed in NonTg TH- RREE mice at 5 mpi, consistent with an
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underlying loss of terminals and dopaminergic dysfunction at this early timepoint. At 5
mpi, A53T TH-RREE mice showed significantly reduced ambulation despite dopamine
concentrations similar to age-matched A53T controls. This may reflect a functional
imbalance among synapses that were lost and those that remained and were
overproducing dopamine (from TH-RREE expression). There was no change in the
amount of dopamine receptors or DARPP-32, further supporting a presynaptic basis for
the locomotor deficit.
The observed toxicity of dopamine only in A53T mice pointed to a potential
synergistic role of dopamine and α-synuclein in mediating neurodegeneration. In cellfree systems, oxidized dopamine has been shown to kinetically stabilize soluble
α-synuclein oligomers (Conway et al., 2001; Norris et al., 2005; Cappai et al., 2005;
Follmer et al., 2007). In SH-SY5Y cultures expressing A53T α-synuclein, dopamine was
able to reduce large intracellular aggregates and increase steady-state levels of soluble
oligomers (Mazzulli et al., 2006; 2007).
neurotoxic species.

α-Synuclein oligomers are thought to be

Lentiviral vector delivery of artificial α-synuclein variants with

enhanced oligomerization into the rat SN resulted in the selective loss of dopaminergic
cells (Winner et al., 2011). Similarly, artificial mutants with impaired β-sheet structure
and increased propensity to form oligomers induced degeneration of dopaminergic nerve
terminals when expressed in worms and overt dopamine cell loss in flies (Karpinar et al.,
2009). However, the toxicity of dopamine-induced α-synuclein oligomers is largely
unexplored. Evidence from studies conducted in vitro suggests that these species can
block their own degradation and that of other substrates by chaperone-mediated
autophagy (Martinez-Vicente et al., 2008), and may also reduce neurotransmitter
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release by inhibition of SNARE complex formation (Choi et al., 2013). Moreover, the
toxicity of endogenous cytosolic dopamine in cultured fetal human dopaminergic neurons
was linked to accumulation of soluble α-synuclein protein complexes (Xu et al., 2002).
Critically, the effects of dopamine on α-synuclein oligomerization in vivo have
not been investigated. We therefore sought to determine if A53T TH-RREE mice had
alterations in oligomer biochemical and/or functional properties. Soluble α-synuclein
oligomers were extracted from the SN and enriched by SEC under non-denaturing
conditions in order to preserve native conformations. Increasing dopamine resulted in
greater total levels of α-synuclein oligomers detected by western blot. The oligomers
included species with Stokes radii of up to 65 Å that were also detected in A53T CtrlVect
mice, consistent with previous characterization of oligomers in aged A53T mice (Tsika et
al., 2010). Larger oligomers of up to 122 Å were uniquely observed in A53T TH-RREE
mice, suggesting that dopamine is capable of modifying oligomer conformations. These
species may reflect dopamine-induced remodeling of existing oligomers, and/or
formation of oligomers from α-synuclein monomers de novo. Additionally, oligomers
with larger Stokes radii may contain a greater number of monomer units than lower Å
species, and/or occupy less compacted arrangements.
Multiple biochemical and imaging approaches were employed to further
characterize the oligomers extracted from SN.

In addition to the well-established

methods such as western blotting and SEC, immunoelectron microscopy was performed
on SEC fractions to visualize mouse-derived α-synuclein oligomers. Currently, there is
no accepted method of specifically imaging α-synuclein oligomers in brain tissue in situ.
However, with our approach, we were able to identify and image oligomers of known
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Stokes radii. Oligomer species from both A53T TH-RREE and A53T CtrlVect mice
were labeled with antibodies directed at the N- or C-terminus of α-synuclein, suggesting
that epitopes at both ends of the protein were exposed. These epitopes were also exposed
in soluble α-synuclein oligomers generated with dopamine in vitro, consistent with
previous imaging by immunoelectron microscopy of recombinant dopamine-induced
α-synuclein oligomers (Norris et al., 2005). Furthermore, LB509 and Syn505 antibodies
are known to react robustly with α-synuclein in pathological inclusions in human disease
brain (Jakes et al., 1999; Duda et al., 2002). The reactivity of both mouse-derived and
recombinant oligomers with these antibodies suggests they may share disease-associated
conformations.
Unlike the α-synuclein species extracted from A53T CtrlVect mice, oligomers
from A53T TH-RREE mice were unable to act as seeds for α-synuclein fibrillization in
vitro. These data are consistent with the known kinetic arrest of recombinant α-synuclein
oligomers comprised of primarily random coil structure in the presence of dopamine
(Conway et al., 2001; Norris et al., 2005). In a comparison of different oligomer species
generated in vitro, α-synuclein oligomers that were toxic to SH-SY5Y cultures were also
incapable of seeding intracellular aggregation of α-synuclein.

Conversely, seeding-

competent oligomers were found to be non-toxic when applied to SH-SY5Y cells
(Danzer et al., 2007). These findings are in line with both our in vivo findings and the
observed toxicity of recombinant dopamine-induced oligomers in primary neuronal
cultures. Dopamine-modified species may resist sequestration into non-toxic fibrils or
inclusions, and may therefore be available to participate in toxic interactions that
ultimately drive neuron death.
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Collectively, this work underscores the potential critical importance of the
interaction of dopamine and α-synuclein in driving disease.

In PD, dopaminergic

terminals are thought to degenerate prior to cell bodies (Cheng et al., 2010), suggesting
that the disease may arise at the synapse. Increasing dopamine levels in A53T mice
recapitulated the substantial loss of terminals that precedes overt nigral cell death,
offering a new model of disease progression in PD. These mice also underwent an
eventual decline in dopamine levels and developed an associated motor deficit,
mimicking the depletion of striatal dopamine and resulting hypokinesia that occurs in PD.
Our findings also demonstrate that dopamine modifies α-synuclein aggregation in vivo,
resulting in oligomer conformations that are biochemically and structurally similar to
neurotoxic oligomers induced by dopamine in vitro. Dopamine-modified α-synuclein
species may mediate neurodegeneration through the disruption of cellular membranes as
previously proposed (Sulzer et al., 2001).

Moreover, damage to synaptic vesicle

membranes could lead to dopamine leakage and further induction of pathogenic αsynuclein oligomers.

2.5 Materials and Methods
Animals. The mice used in this study were homozygous for expression of human
A53T α-synuclein under the mouse PrP promoter (line M83). These mice undergo spinal
cord degeneration at approximately 18 months of age in our colony, and the phenotype
has been described previously (Giasson et al., 2002). Any animals showing symptoms of
spinal cord degeneration, i.e. hunched back, altered gait, or hindlimb paralysis, were
excluded from the study. NonTg littermates were also used for experiments. No care
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was taken as to the sex of the animals. Mice were randomly assigned to the lentiviral
vector injection groups.
Production of Lentiviral Vectors and Determination of Titer. Generation of
human tyrosine hydroxylase-1 containing the R37E/R38E mutation (TH-RREE)
construct has been previously described (Mazzulli et al., 2006). The coding sequence
was removed from the pcDNA3.1 vector and was subcloned into the self-inactivating
pTY-linker lentiviral expression vector at the Pme1 site downstream of the CMV
promoter. Generation of replication-deficient pseudotyped HIV-derived lentiviral vectors
was achieved by transient co-transfection of HEK293T cells with the expression vector
along with the vectors carrying the additional transcripts required for encapsulation,
packaging and envelope proteins. 24 hours after the cells were seeded into 150 mm
dishes coated with poly-D-Lysine they were transiently transfected with a mixture
containing 550 µg of the pTY-TH-RREE expression vector, 357.5 µg of CMVD82
packaging vector, and 192.5 µg of pVSV-G envelope vectors using the calcium
phosphate transfection protocol. The culture medium was changed every day and the
media containing the virus was collected 72 hours post-transfection, filtered through 0.45
µm membranes, and concentrated by ultracentrifugation at 50,000 g for 2 hours at 4°C.
The viral pellet was subsequently re-suspended in 800 µL of DMEM medium to make a
concentrated viral stock. An empty vector control virus containing all elements except
for the TH-RREE gene (CtrlVect) was generated in parallel and both viruses were
obtained from the University of Pennsylvania Vector Core.
To determine vector functionality and viral titer, SH-SY5Y human neuroblastoma
cells (American Type Culture Collection) were plated in 24-well plates at 5x104
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cells/well in DMEM/F12 medium containing 10% heat-inactivated fetal bovine serum,
100 U/ml penicillin, and 100 µg/ml streptomycin. The cells were allowed to recover for
2 days and were then differentiated for 5 days with 20 µM retinoic acid. The cells were
infected with different dilutions of lentivirus containing either an empty vector or
TH-RREE

expression

vector

and

the

viral

titers

were

calculated

by

TH

immunocytochemistry.
Stereotaxic Injection of Lentiviral Vector into the SN. A53T α-synuclein
transgenic mice or non-transgenic littermates received bilateral lentiviral vector injections
at 10 months of age. The mice were placed into an anesthesia chamber connected to an
isofluorane delivery system to induce anesthesia. The mice were then placed into a
stereotaxic head holder, an anesthesia mask was fitted, and an incision was made in the
skin. Small bilateral holes were drilled into the skull according to the coordinates for the
SN in the mouse brain (anterior-posterior -3.3 mm from bregma, mediolateral 1 mm) and
a 30g Hamilton syringe was inserted slowly to 4 mm dorsoventral depth. 2 µl of the viral
concentrate (5x107 IU/ml) was injected into the SN at a rate of 0.25 µl/min, and the
needle was left in place for an additional 5 min before being slowly withdrawn, in order
to minimize leakage of the injected fluid. The skin was sutured sterilely and the animals
were monitored until they recovered from anesthesia. All animal work was conducted
according to National Institute of Health guide for the care and use of laboratory animals
and were approved by the Children’s Hospital of Philadelphia.
Motor Function Testing. All behavioral tests were conducted 1 week prior to
sacrifice. Mice were habituated to the testing room for 2 hours before testing. To
measure open field activity, the mice were singly housed and the cage was placed
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inside a laser monitoring device consisting of an open, rectangular frame containing
sensors (Opto-M3 activity meter, Columbus Instruments). The number of infrared beam
breaks was quantified over a 12-hour period during the dark cycle from 6 pm to 6 am
using Multi Device Interface software (Columbus Instruments). Data was collected for 3
consecutive days for each animal, and the average of the 3 days was used as n = 1 for
each mouse. Food and water were available ad libitum.
To assess motor coordination and balance, mice were tested on the Rotarod (Ugo
Basile, model 7650). The mice were acclimated to the apparatus with four training
sessions of 5 min each at 4 rpm, followed by 5 min of rest in the home cage. Testing was
performed one hour later with two trials in which speed was accelerated from 4 to 40 rpm
in 300 sec. The latency to fall off the rotarod within this time period was recorded and
the average of the two trials was used as n = 1 for each mouse.
Immunohistochemistry and Stereological Cell Counts.

For histological

analysis the mice were deeply anesthetized and perfused transcardially with saline
followed by 4% PFA in 0.1 M phosphate buffer (pH 7.4). The brains were post-fixed
overnight at 4°C in 4% PFA and then cryoprotected in 30% sucrose solution for 2 days at
4°C. The brains were submerged in dry ice-chilled isopentane for 30 sec and then stored
at -80°C until sectioning. On the day of sectioning, brains were mounted on chucks with
OCT (Tissue-Tek) and the brainstem, SN, and striatum were each sectioned using a
cryostat (Leica, Jung Frigocut 2800N). Free-floating coronal sections of alternating 10
and 30 μm thickness were collected from each region and stored at 4°C in 0.1 M
phosphate buffer containing 0.01% sodium azide.
The sections were quenched in 5% H2O2 in methanol for 30 min, followed by
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antigen retrieval by boiling in citrate solution pH 6 for 10 min. The tissue was blocked
for 1 hour at RT with 5% NGS, 3% BSA in PBS containing 0.1% Triton X-100, and then
incubated overnight at 4°C with primary antibody diluted in blocking buffer. Antibodies
were used against VMAT2 (rabbit, 1:20000; courtesy of Dr. Gary Miller at Emory
University, Atlanta, GA), TH (rabbit, 1:2000, Calbiochem 657012), and Syn505 (mouse,
1:5000, courtesy of Dr. Virginia M. Lee at University of Pennsylvania, Philadelphia, PA).
Incubation with biotin-conjugated secondary antibodies was followed by avidin-biotinperoxidase complex, each for 1 hour at RT, and visualization by 3,3-diaminobenzidine
(DAB) for 1 min (ABC Elite, Vector Laboratories).
counterstained with Cresyl Violet.

In some cases, sections were

The tissue was then mounted, dehydrated in an

increasing alcohol series and cleared in xylenes, and coverslipped with Permount
mounting medium. Slides were scanned by the Children’s Hospital of Philadelphia
Pathology Core facility. Quantification of VMAT2 staining intensity in the striatum was
performed using Image J software (National Institutes of Health).
Unbiased stereological quantification of neurons in the SN was performed as
described previously (Tieu et al., 2003). Briefly, 30 μm sections spaced 90 μm apart
were selected in order to represent the full rostro-caudal axis of the SN. The sections
were stained with Cresyl Violet and the Nissl-positive neurons were blindly counted
using the optical fractionator method (StereoInvestigator; MBF Bioscience).
Catechol Quantification by HPLC with Electrochemical Detection. Striatal
tissues were homogenized by sonication in 10 volumes of 0.1 M perchloric acid
containing 1 µM 3,4 dihydroxybenzylamine as an internal standard. The samples were
centrifuged at 16,000 g for 10 min at 4°C and the supernatants were filtered through
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0.22 µm filters. Catechols were resolved on a reverse-phase C18 Luna column (150x4.6
mm, 5 µm; Phenomenex) as previously described (Mazzulli et al., 2006). Protein pellets
were solubilized in 50 mM Tris pH 7.4 containing 2% SDS and protein concentration
was determined using the BCA microassay kit (Pierce).

Monoamine levels were

normalized to protein concentration and expressed as femtomoles analyte /µg of protein.
Sequential Extraction and Native Size Exclusion Chromatography. Striatal or
SN tissue from individual mice was homogenized in 10 volumes of lysis buffer: 1%
Triton X-100 in 20 mM HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM EGTA, and
protease inhibitor cocktail (P2714, Sigma). The tissue was grinded with a mechanical
homogenizer and centrifuged at 16,000 g for 10 min at 4°C. The pellet was further
extracted by sonication in 2% SDS, 50 mM Tris pH 7.4 with protease inhibitor cocktail,
boiling at 95°C for 10 min, and centrifugation at 16,000 g for 10 min. The resulting
supernatant was designated the Triton-insoluble fraction.

Protein concentration was

determined using the BCA assay (Pierce).
For size exclusion chromatography (SEC), 500 µg of Triton-soluble SN tissue in a
total volume of 270 µl was loaded onto a Superdex 200 HR10/30 column (GE
Healthcare) connected to an Agilent 1100 series HPLC system. Mobile phase consisted
of 25 mM HEPES and 150 mM NaCl, pH 7.25 and the flow rate was set to 0.3 mL/min.
Fractions corresponding to 122-94, 94-81, 81-72, 72-65, 65-59, 59-54, 54-50, 50-45, 4541, 41-38, 38-34, and 34-32 Å were each pooled and concentrated with 3,000 NMWL
Ultracel Microcon filters (Millipore). Fractions 122-72, 65-41, and 38-32 were further
combined to enhance the α-synuclein signal on SDS-PAGE. The SEC column was
calibrated using globular protein standards (GE Healthcare).
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Western Blotting. Proteins sequentially extracted or further fractionated by SEC
were run on 10 or 12% SDS-PAGE gels and transferred to PVDF membranes. The
membranes were blocked for 1 hour at RT in 5% (w/v) milk in 20 mM Tris pH 7.4, 150
mM NaCl and 0.1% Tween. Incubation with primary antibodies diluted in blocking
buffer was overnight at 4°C. Antibodies used against synaptic proteins were TH (rabbit,
1:4000, Calbiochem 657012), DAT (rat, 1:1000, Millipore MAB369), D1 receptor (rat,
1:1000, Sigma D2944), D2 receptor (rabbit, 1:1000, Millipore AB5084P), DARPP-32
(rabbit, 1:1000, Cell Signaling 2306S). Antibodies directed against α-synuclein were
LB509 (mouse, 1:1000), Syn505 (mouse, 1:1000), and SNL-4 (rabbit, 1:1000), all
courtesy of Dr. Virginia M. Lee at University of Pennsylvania, Philadelphia, PA.
Loading controls for Triton-soluble proteins were GAPDH (mouse, 1:10000, Abcam
ab8245), NSE (rabbit, 1:4000, Abcam ab53025), and Actin (rabbit, 1:1000, Sigma
A2066). The loading control for Triton-insoluble proteins was Vimentin (mouse, 1:1000,
Abcam ab8069). Membranes were incubated for 1 hour at RT with secondary antibodies
conjugated to IRDye 680 or 800 (1:5000, Rockland) and then scanned using an Odyssey
Infrared Imaging System (Li-Cor). Quantification of protein levels was performed using
ImageStudio software (Li-Cor) and was normalized to loading control levels. For αsynuclein oligomer bands, all individual immunobands >19 kD that were detected were
quantified and the intensities summed, and the total was divided by the total NSE.
Near-infrared (nIRF) scanning of oxidized catechols was performed as described
previously (Mazzulli et al., 2016). Briefly, prior to transfer the SDS-PAGE gels were
scanned in the 700 nm channel at intensity 10 on an Odyssey Infrared Imaging System
(Li-Cor).
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Immunoelectron Microscopy of SEC Fractions. SEC fractions from SN tissue
corresponding to low (41-65) and high (72-122) Å Stokes radii or dopamine-incubated
recombinant α-synuclein were applied to 300 mesh carbon-coated grids and blocked with
1% BSA in 20 mM Tris pH 7.4, 150 mM NaCl. The α-synuclein oligomers were labeled
with the Syn505 antibody against the N-terminus or LB509 antibody against the Cterminus, followed by 10 nm gold conjugated secondary (Electron Microscopy Sciences).
Grids were negatively stained with 1% uranyl acetate and imaged at the University of
Pennsylvania Electron Microscopy Resource Laboratory.

Control samples were

immunodepleted of α-synuclein (see below) prior to grid preparation or had primary
antibody omitted.
In Vitro Aggregation and Seeding Assays. Recombinant human wild type αsynuclein was expressed and purified as described previously (Tsika at el., 2010).
Purified α-synuclein was incubated at 6 mg/mL (415 µM) with or without equimolar
dopamine at 37°C and shaking at 1400 rpm for up to 6 days. At indicated time points,
fibrillar content of the reaction mixture was assayed by the addition of Thioflavin T
(Sigma) to a final concentration of 25 µM. Fluorescence emission was measured at 482
nm during excitation at 450 nm. Sedimentation analysis was performed by centrifugation
at 16,000 g for 10 min at 4°C. The supernatants and pellets were boiled in SDS sample
buffer at 95°C for 10 min. α-Synuclein aggregates were resolved by SDS-PAGE and the
gels were stained with Coomassie Blue R-250. Circular dichroism spectra were obtained
using a Jasco J-810 spectropolarimeter at the Children’s Hospital of Philadelphia Protein
Core facility. The protein was diluted to 20 µM in 0.05 M KH2PO4 pH 7.8. Spectra were
corrected for baseline measurement of an equivalent volume of PBS diluted in
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KH2PO4 buffer.
Seeding assays were performed by incubating 5 µg total protein from pooled
oligomeric SEC fractions (41-122 Å) with 425 µg fresh recombinant α-synuclein (300
µM final concentration) at 37°C and shaking at 1400 rpm. Aliquots at indicated time
points were analyzed by Thioflavin T.

To immunodeplete α-synuclein for control

samples, pooled SEC fractions were incubated overnight at 4°C with LB509 antibody at a
1:5 ratio of antibody to total µg protein. Protein G-conjugated beads (Sigma) were
equilibrated in 25 mM HEPES, 150 mM NaCl, pH 7.4 and incubated with the
immunocomplexes for 1 hour at 4°C. α-Synuclein oligomers were then pulled down by
centrifugation at 2000 g for 2 min, and the resulting supernatant was used for
experiments.
Primary Neuronal Cultures.

Hippocampal neurons were provided by the

University of Pennsylvania Neuron Culture Service Center.

After dissection from

C57BL/6 mouse embryos at day 18-19, cells were mechanically dissociated, trypsinized,
and seeded at 100,000 cells per well into 24-well plates freshly coated with 50 µg/ml
poly-D-lysine (Sigma). After plating, neurons were cultured for 2 hours in culture media
containing 5% heat-inactivated fetal bovine serum, 1% Glutamax, 2% B-27 supplement,
100 U/ml penicillin, 100 µg/ml streptomycin in Neurobasal media (all from Invitrogen).
After 2 hours, the media was changed to culture media without fetal bovine serum to
discourage survival of glial cells. Twice per week, half of the media was replaced with
fresh culture media.
Following one week in culture, neurons were treated with dopamine-incubated
α-synuclein (from day 4-6 of in vitro aggregation) at a final concentration of 1
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µM.

Control conditions were equivalent doses of PBS, monomeric α-synuclein, or

dopamine that had been incubated in parallel under aggregation conditions but without αsynuclein.

Two weeks post-treatment, cell viability was assayed using calcein AM

(Sigma) and propidium iodide (PI) (Sigma) incubated for 20 min at RT at final
concentrations of 3 µM in PBS. Fluorescence images were obtained using MetaMorph
software (Molecular Devices) and an inverted Olympus IX70 microscope equipped with
an IX-FLA fluorescence observation attachment (Olympus Optical Co., Tokyo, Japan).
For quantification of viable cells (calcein-positive and PI-negative), 10 random fields of
view were blindly counted per well, with at least 100 total cells counted per replicate.
To image human α-synuclein in treated neurons, cells were labeled in a two-stage
protocol as previously described (Volpicelli-Daley et al., 2011). Two weeks following
treatment, cells were live-incubated in media containing Syn204 antibody (mouse IgG2a,
1:500) for 1 hour at 4°C to label extracellular α-synuclein. The cells were then fixed with
4% PFA for 20 min at RT, and permeabilized with 0.1% Triton X-100 in 5% NGS, 3%
BSA in PBS for 1 hour at RT. Cells were incubated with LB509 (mouse IgG1, 1:500)
overnight at 4°C to label both extracellular and intracellular α-synuclein. Secondary
antibodies conjugated to Alexa Fluor (anti-mouse IgG1 488, 1:500, Thermo Fisher
A21121; anti-mouse IgG2a 594, 1:500, Thermo Fisher A-21135) were incubated for 1
hour at RT. The staining was imaged by laser-scanning confocal microscopy (Olympus
Fluoview).
Statistics. All statistical analysis was done using Prism 6 software (GraphPad).
Two-tailed unpaired Student’s t test was used for all comparisons between two groups.
For comparisons with multiple groups, one- way ANOVA with Tukey’s correction for
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multiple comparisons was used.

Specifically for Thioflavin T assays with multiple

groups measured over time, repeated-measures two-way ANOVA with Tukey’s or
Bonferroni’s correction for multiple comparisons was used.

All experiments were

performed at least twice, with measurements from the same samples treated as technical
replicates and averaged to obtain final values.
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2.7 Supplementary Information

Figure 2.S1: Increased TH expression and steady-state catecholamine concentrations in
SH-SY5Y cells transduced with TH-RREE vector. (a) Schematic representation of the
lentiviral vectors used in this study. TH-RREE contained the gene for human tyrosine
hydroxylase isoform 1 (hTH-1) with mutations R37E, R38E rendering TH insensitive to feedback
inhibition by dopamine. The gene was absent from the empty vector control (CtrlVect), while all
other elements were retained. (b) Western blot analysis of lysates showed TH protein only in
TH-RREE transduced cells. Neural specific enolase (NSE) was used as a loading control. (c) TH
immunofluorescence confirmed expression in TH-RREE transduced cells. Scale bar, 100 μm.
(d) Catecholamines were detected in cells treated with TH-RREE lentivirus. ND, not detected.
The data are presented as mean ± s.e.m. (n = 3 except n = 6 for DA TH-RREE and DOPAC THRREE).
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Figure 2.S2: TH-RREE vector increases TH expression in A53T mice. (a) TH levels were
increased in the striatum in A53T TH-RREE mice compared with A53T CtrlVect at 5 mpi.
GAPDH was used as a loading control. The data are presented as mean ± s.e.m. (n = 3; twotailed unpaired Student’s t test). (b) TH staining was increased in both the SN (left panels) and
striatum (right panels) of A53T TH-RREE mice at 5 mpi. Cresyl Violet (Nissl) counterstain.
Scale bar, 10 μm. *P < 0.05.
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Figure 2.S3: Postsynaptic markers remain unchanged by lentiviral vector treatment.
Striatal levels of D1 (a,b) and D2 (a,c) postsynaptic receptors were unaltered in TH-RREE
injected A53T and NonTg mice compared with CtrlVect-injected mice. The postsynaptic
signaling molecule DARPP-32 was also unaffected by viral treatment (a,d). All quantification
was normalized to actin loading control. The data are presented as mean ± s.e.m. (D1R, n = 3
except n = 4 for NonTg CtrlVect; D2R, n = 3 except n = 4 for NonTg CtrlVect; DARPP-32, n =
3; one-way ANOVA with Tukey’s correction for multiple comparisons).
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Figure 2.S4: Loss of striatal dopamine in A53T mice cannot be accounted for by metabolism
to DOPAC or formation of dopamine-protein adducts. (a) Levels of DOPAC in the striatum
remained unchanged over time regardless of lentiviral treatment. The data are presented as mean
± s.e.m. (CtrlVect, n = 3; TH-RREE, n = 6 for 2.5 mpi and n = 4 for 5 mpi; one-way ANOVA
with Tukey’s correction for multiple comparisons). (b-c) Triton-soluble (S) and insoluble (P)
extracts of striatal tissue from mice at 2.5 or 5 mpi were analyzed by SDS-PAGE and nearinfrared fluorescence (nIRF). Total levels of dopamine-protein adduct (combined soluble and
insoluble nIRF signal) did not change either between injection groups or within groups over time.
The data are presented as mean ± s.e.m. (n = 3; one-way ANOVA with Tukey’s correction for
multiple comparisons).
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Figure 2.S5: Analysis of inclusion pathology and insoluble α-synuclein in A53T mice. (a)
Regardless of lentiviral treatment, α-synuclein inclusion pathology, as detected by Syn505
staining, was abundant in brainstem (BS) and absent in SN of A53T mice at 5 mpi. Scale bar, 20
μm. (b-d) At 5 mpi, SN from A53T mice was sequentially extracted with buffers containing 1%
Triton followed by 2% SDS. Triton-insoluble/SDS-soluble fractions from A53T TH-RREE and
A53T CtrlVect contained similar levels of monomeric α-synuclein as assessed by LB509 (b),
Syn211 (c), and SNL-4 (d) antibodies. Vimentin (Vim) was used as a loading control, and
appears for Syn211 and SNL-4 as the same blot since the same membrane is shown. The data are
presented as mean ± s.e.m. (LB509, n = 3; Syn211 and SNL-4 n = 6 except n = 4 for CtrlVect;
two-tailed unpaired Student’s t test).

70

Figure 2.S6: Further characterization of α-synuclein and dopamine derived from A53T
mice. (a-b) Triton-soluble SN from A53T TH-RREE and A53T CtrlVect mice at 5 mpi was
fractionated by size exclusion chromatography, and the resulting fractions were analyzed by
western blot using α-synuclein antibodies Syn211 (C-terminal) (a) and SNL-4 (N-terminal) (b).
Oligomer bands that uniquely appear in 122 Å fractions from TH-RREE mice are indicated by
arrows. Neural specific enolase (NSE) was used as a loading control, and appears for Syn211 and
SNL-4 as the same blot since the same membrane is shown. (n = 4). (c) The SDS-PAGE gels
were scanned for near-infrared fluorescence, which revealed oxidized dopamine (arrow) only in
72-122 Å fractions from A53T TH-RREE mice. (n = 4).
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3.1 Abstract
α-Synuclein is a conserved, abundantly expressed protein that is partially
localized in pre-synaptic terminals in the central nervous system. The precise biological
function(s) and structure of α-synuclein are under investigation. Recently, the native
conformation and the presence of naturally occurring multimeric assemblies have come
under debate. These are important deliberations because α-synuclein assembles into
highly organized amyloid-like fibrils and non-amyloid amorphous aggregates that
constitute the neuronal inclusions in Parkinson’s disease and related disorders. Therefore
understanding the nature of the native and pathological conformations is pivotal from the
standpoint of therapeutic interventions that could maintain α-synuclein in its
physiological state. In this review, we will discuss the existing evidence that define the
physiological states of α-synuclein and highlight how the inherent structural flexibility of
this protein may be important in health and disease.

3.2 Introduction
α-Synuclein is a soluble protein that is highly conserved in vertebrates and
abundantly expressed in nervous tissue (Jakes et al., 1994). It was first discovered in
1988 in association with purified synaptic vesicles from the Torpedo electric ray
(Maroteaux et al., 1988). Soon afterward α-synuclein was found to be widely distributed
across the mammalian brain and localized to presynaptic nerve terminals, suggesting
functions related to neurotransmission (Iwai et al., 1995). Independent of these reports,
α-synuclein was identified as the precursor to a hydrophobic peptide found in
Alzheimer’s disease senile plaques, termed the non-Aβ component of Alzheimer’s
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disease amyloid (NAC) (Uéda et al., 1993). The α-synuclein gene was also dynamically
regulated during song learning in zebra finch, supporting a role in synaptic plasticity
(George et al., 1995).
The discovery of a mutation in the α-synuclein gene that was associated with
autosomal dominant inheritance of Parkinson’s disease (PD) provided the impetus for a
major shift in α-synuclein research (Polymeropoulos et al., 1997).

PD is a neuro-

degenerative disorder primarily characterized by the loss of dopamine-producing neurons
in the substantia nigra pars compacta resulting in motor impairment. Since the original
publication of the A53T mutation, several mutations, as well as multiplications of the αsynuclein gene have been linked to PD (Chartier-Harlin et al., 2004; Krüger et al., 1998;
Lesage et al., 2013; Pasanen et al., 2014; Proukakis et al., 2013; Singleton et al., 2003;
Zarranz et al., 2004; Ferese et al. 2015) Furthermore, several antibodies against αsynuclein robustly detect the well-known pathoanatomical features of PD, Lewy bodies
and Lewy neurites, in postmortem brain tissue from patients with sporadic PD as well as
other related neurodegenerative disorders (Baba et al., 1998; Spillantini et al., 1997;
Takeda et al., 1998). The finding that wildtype α-synuclein was detected in Lewy bodies
and Lewy neurites prompted the publication of numerous studies that investigated the
biochemistry and biology of α-synuclein. Despite the rather impressive body of work
several fundamental questions remain: What is the physiological function of α-synuclein?
What is the structure of native α-synuclein? What factors contribute to the induction of
aggregation-competent conformational states of α-synuclein? In this review, we will
briefly review the evidence for the different biological functions and discuss ongoing
efforts to precisely define physiological structures of α-synuclein.
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3.3 The physiological function(s) of α-synuclein
The initial studies indicated that α-synuclein is not required for neuronal
development or synapse formation, but instead may modulate synaptic activity.

In

rodents, α-synuclein is detected close to the time of birth and continues to increase until
one month of age, when it reaches a steady-state level that is maintained throughout
adulthood (Shibayama-Imazu et al., 1993).

Similarly, in cultured rat neurons the

development of synapses precedes α-synuclein expression and translocation to axonal
terminals (Murphy et al., 2000; Withers et al., 1997). The hypothesis that α-synuclein
regulates synaptic activity was directly tested in mice lacking α-synuclein. α-Synuclein
null mice develop normal brain architecture and synaptic contacts, and do not exhibit
gross behavioral phenotypes (Abeliovich et al., 2000). However, subtle abnormalities in
activity-dependent neurotransmitter release have been observed.

Upon repeated

stimulation, dopaminergic synapses from α-synuclein null mice sustain highly elevated
dopamine release (Abeliovich et al., 2000; Yavich et al., 2004). Functional redundancy
among α-synuclein and the other synuclein family members, β- and γ-synuclein, may
account for the mild phenotypes observed in the single knockout. In α/β-synuclein
double knockout mice, synaptic plasticity appears unaltered relative to α-synuclein single
knockouts, although dopamine levels in the striatum are reduced (Chandra et al., 2004).
The importance of synucleins is particularly highlighted by α/β/γ-synuclein triple
knockouts, which have decreased life span and late-onset synaptic dysfunction compared
with wildtype mice (Burré et al., 2010; Greten-Harrison et al., 2010). Triple knockouts in
another study had motor deficits and decreased striatal dopamine, along with abnormal
dopamine neurotransmission (Anwar et al., 2011).
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Collectively,

these

reports

emphasize the important role of the synucleins in long-term synaptic maintenance and
plasticity.

3.3.1 Synaptic vesicle trafficking
Examination of the role of α-synuclein in the synaptic vesicle cycle has yielded
conflicting results. Depletion of α-synuclein from rodent hippocampal neurons both in
vivo and in vitro induces a significant loss of undocked synaptic vesicles, suggesting that
α-synuclein acts to replenish or maintain the resting and/or reserve vesicle pools (Cabin
et al., 2002; Murphy et al., 2000). In contrast, another study found that increasing αsynuclein in rodent hippocampal neurons reduces the recycling pool of vesicles (Nemani
et al., 2010). The effect of α-synuclein on vesicles docked at the plasma membrane prior
to exocytosis is similarly unclear. Knockout or knockdown of α-synuclein in rodent
hippocampal neurons results in either a decrease or no change in the number of docked
vesicles (Cabin et al., 2002; Murphy et al., 2000). Conversely α-synuclein expression in
PC12 cells causes an accumulation of vesicles at the plasma membrane and impairment
of exocytosis (Larsen et al., 2006).

However, in mice modestly overexpressing α-

synuclein (levels are not associated with neurotoxicity), hippocampal synapses display a
redistribution of vesicles away from the active zone. The density of vesicles in synaptic
boutons is also reduced, consistent with α-synuclein-mediated inhibition of vesicle
clustering. This is supported by α-synuclein-induced defects in vesicle re-clustering
following endocytosis in rat hippocampal neurons (Nemani et al., 2010). Still, opposing
results have been obtained from yeast, in which α-synuclein expression results in massive
accumulations of vesicles that co-localize with Rab GTPases (Gitler et al., 2008;
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Chen et al., 2008b). Likewise, α-synuclein has been shown to restrict vesicle diffusion
away from synapses in mouse hippocampal neurons (Wang et al., 2014). Several lines of
evidence, therefore, support the participation of α-synuclein in synaptic vesicle
trafficking, though the specific steps for which it may be most important, i.e. vesicle
docking, recycling and/or re-clustering, remain unclear.

3.3.2 Chaperone-like activity and neurotransmitter release
α-Synuclein and the other synuclein family members may act as molecular
chaperones, facilitating neurotransmitter release. Cysteine-string protein α (CSPα) is a
chaperone that is essential for synaptic health; its deletion in mice leads to a decrease in
SNARE protein complexes, nerve terminal degeneration, motor impairment and death.
When expressed in CSPα-deficient mice, α-synuclein is able to rescue this degenerative
phenotype and restore levels of SNARE complexes in synaptic terminals. Moreover,
mice lacking both α-synuclein and CSPα exhibit an exacerbated phenotypic decline
(Chandra et al., 2005). These findings suggest that α-synuclein is able to complement the
activity of CSPα in promoting synapse integrity. Direct evidence for the interaction of
α-synuclein with SNARE complexes was documented by co-immunoprecipitation of αsynuclein with SNARE proteins and specific binding to the vesicle-associated SNARE
protein synaptobrevin-2. In mammalian cells and purified in vitro systems, α-synuclein
dose-dependently facilitates SNARE complex assembly (Burré et al., 2010). Additional
support for chaperone-like activity includes sequence homology between α-synuclein and
14-3-3 protein chaperones as well as the association of α-synuclein with 14-3-3 and its
binding partners in rat brain (Ostrerova et al., 1999). α-, β-, and γ-synucleins are
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also able to prevent the aggregation of denatured proteins in vitro (Souza et al., 2000a),
further supporting a conserved chaperone-like function of synucleins and the existence of
several protein-protein interactions that facilitate synaptic function.

3.3.3 Putative role in neurotransmitter synthesis and reuptake
Published

evidence

indicates

that

α-synuclein-mediated

protein-protein

interactions may modulate dopamine synthesis and recycling. α-Synuclein may inhibit
the activity of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine
synthesis. α-Synuclein and TH co-immunoprecipitate from rat striatal tissue and MN9D
dopaminergic cells and α-synuclein was shown to inhibit TH activity in MN9D and PC12
cells, potentially through PP2A phosphatase-mediated reduction of serine 40
phosphorylation of TH (Peng et al., 2005; Perez et al., 2002). α-Synuclein may also
interact with and inhibit the activity of aromatic amino acid decarboxylase, which
catalyzes the conversion of L-DOPA to dopamine (Tehranian et al., 2006).

Thus,

α-synuclein may serve as a negative regulator of dopamine synthesis, though further
validation of these findings is necessary.

Several reports have also implicated α-

synuclein in the regulation of the dopamine transporter (DAT), though the evidence is
conflicting with regards to the functional consequences. Direct binding of α-synuclein to
DAT has been demonstrated in multiple studies. However, α-synuclein does not appear
to alter DAT function, but rather in various cellular contexts can promote or inhibit DAT
trafficking to the plasma membrane (Oaks and Sidhu, 2011). Elucidating the relationship
between α-synuclein and DAT requires further investigation.
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3.4 α-Synuclein structural flexibility
3.4.1 Primary sequence
The primary sequence of α-synuclein consists of 140 amino acids with a predicted
molecular mass of 14,460.16 Da and an isoelectric point of 4.67 (Figure 3.1). The
sequence of α-synuclein is composed of three functionally defined domains.

The

N-terminal region (amino acids 1-60) is characterized by the presence of unique and
highly conserved sequence of imperfect tandem repeats with a central consensus motif of
K(A)-T(A,V)-K(V)-E(Q,T)-G(Q)-V(A).

These motifs spanning residues 10-86 are

projected to form two amphipathic α-helices and are characteristic of several proteins
such as apolipoproteins that bind reversibly to membranes (George et al., 1995;
Maroteaux et al., 1988). Indeed the structure of membrane bound α-synuclein contains
two α-helices (amino acids 3-37 and 45-92) in a roughly antiparallel arrangement with a
short linking region (Ulmer et al., 2005). These helices are stabilized by interaction with
a variety of phospholipid bilayers, though α-synuclein interacts preferentially with
membranes of high curvature and an abundance of acidic phospholipids, properties
consistent with those of synaptic vesicles (Davidson et al., 1998; Zhu et al., 2003a).

Figure 3.1: Primary sequence of human α-synuclein. Green color indicates the imperfect
tandem repeats. Known mutations are indicated in red. The hydrophobic NAC domain is
underlined. The major sites of posttranslational modifications identified in vivo are highlighted
in blue (Ac, acetylation; Ub, ubiquitination; NO2, nitration; and PO3- phosphorylation).
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Upon interaction with membranes of low curvature α-synuclein adopts a distinct
secondary structure characterized by a single extended helix that includes both previously
described helical domains and the linker region (amino acids 38-44) (Ferreon et al., 2009;
Georgieva et al., 2010; Trexler and Rhoades, 2009). All known mutations associated
with familial PD (A30P, E46K, H50Q, G51D, A53E, and A53T) are found in the Nterminal domain (Krüger et al., 2008; Lesage et al., 2013; Pasanen et al., 2014;
Polymeropoulos et al., 1997; Proukakis et al., 2013; Zarranz et al., 2004).

These

mutations, with the exception of G51D, A53E, and A30P, increase the propensity of αsynuclein to form insoluble aggregates and produce morphologically distinct aggregate
species (Ghosh et al., 2014; Giasson et al., 1999; Greenbaum et al., 2005; Lesage et al.,
2013; Mahul-Mellier et al., 2015; Narhi et al., 1999). Though the precise mechanism by
which these mutations promote aggregation has not been conclusively shown, evidence
implicate an accelerated formation of oligomers (Conway et al., 2000b) likely due to the
destabilization of the native N-terminal conformation (Bertoncini et al., 2005a; Burré et
al., 2015; Coskuner and Wise-Scira, 2013; Dettmer et al., 2015).
Amino acids 61-95 compose the hydrophobic NAC domain (Uéda et al., 1993).
This region contains a sequence of amino acids (71-82) necessary and sufficient for
α-synuclein self-assembly into amyloid fibrils (Giasson et al., 2001). Recently the crystal
structures of residues 68-78 (termed NACore), and residues 47-56 (PreNAC) were
resolved by the use of micro-electron diffraction, revealing that strands in this region
stack in-register into β-sheets that are typical of amyloid assemblies (Rodriguez et al.,
2015).
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The C-terminal domain (96-140) is rich in negatively charged amino acids
(contains 10 glutamate and 5 aspartate residues) and was originally proposed to be
essential for maintaining the solubility of the protein. The presence of 5 proline residues,
which are known to induce turns and disrupt secondary protein structure, suggested that
this region is devoid of secondary structure (George et al., 1995; Ulmer et al., 2005).
However, the C-terminus was shown to form transient, long-range interactions with the
N-terminus resulting in the formation of multiple compact monomeric structures
(Bertoncini et al., 2005a; Dedmon et al., 2005).

These compacted structures of

α-synuclein are temperature sensitive and are resistant to aggregation. The data also
indicated that at elevated temperatures the C-terminus assumes an extended conformation
that liberates N-terminal associations and enables aggregation (Bertoncini et al., 2005b;
Dedmon et al., 2005). Moreover, C-terminally truncated forms of α-synuclein aggregate
faster than full length protein (Hoyer et al., 2004; Li et al., 2005b).

Truncated α-

synuclein has been detected in the brains of both control (non-disease) and PD patients.
Cleavage of full-length protein at residues D115, D119, N122, D125 and Y133 was
documented in α-synuclein extracted from LBs (Anderson et al., 2006).
The C-terminus appears to be important for the interaction of α-synuclein with
other proteins and for the interaction with small molecules (Burre et al., 2012; Burré et
al., 2010; Conway et al., 2001; Mazzulli et al., 2006; Souza et al., 2000b; Woods et al.,
2007). Additionally, it contains the major sites of metal binding and post-translational
modifications. Binding of iron, copper, and other metals has been shown to influence αsynuclein function and aggregation (Uversky et al., 2001a). Addition of Fe(III), but not
Fe(II)

to

preformed

oligomers

of

α- synuclein accelerates aggregation, raising
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the question of metal binding at different points during the aggregation process (Kostka
et al., 2008). Cu(II) is unique among metals at accelerating aggregation of α-synuclein at
physiologically relevant concentrations. The sole histidine residue H50 in α-synuclein
was found to be critical for Cu(II) binding (Rasia et al., 2005) whereas other divalent
metal ions, including Mn(II), Co(II), Ni(II) and Fe(II), preferentially bind to the Cterminus of α-synuclein at residues D121, N122, and E123 (Binolfi et al., 2006).

3.4.2 Post-translational modifications
α-Synuclein undergoes a number of post-translational modifications, including Nterminal acetylation, serine and tyrosine phosphorylation, lysine ubiquitination and
tyrosine nitration (Oueslati et al., 2010; Barrett & Greenamayer 2015). α-Synuclein
purified under mild conditions is acetylated in the N-terminus.

The N-terminal

acetylation may account for the formation of an oligomeric form of the protein with
partial α-helical structure (Trexler and Rhoades, 2012).

However, semisynthetic

production of N-terminally acetylated α-synuclein demonstrated that modified and
unmodified versions of the protein share similar secondary structure, aggregation
propensities, and membrane binding (Fauvet et al., 2012b). NMR studies indicated that
the first 12 residues undergo a chemical shift due to N-terminal acetylation.

This

modification also appears to stabilize the helicity of the N-terminus within the context of
the full-length protein, and increases the affinity of α-synuclein for lipids (Dikiy and
Eliezer, 2014).
Mass spectrometry-based methodologies revealed that α-synuclein extracted from
human Lewy bodies was phosphorylated at S129 (Fujiwara et al., 2002). An antibody
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raised against phosphorylated S129 was then used to show that α-synuclein was
phosphorylated at this site only in subjects with disease and that S129 phosphorylated
α-synuclein was present only in the Triton-X- and Sarkosyl-insoluble, urea soluble
fraction. These data indicated that some form(s) of aggregated α-synuclein and not the
soluble protein is targeted for phosphorylation at S129. Indeed in vitro data showed that
purified fibrils of α-synuclein are substrates for casein kinase 1 or 2 (Waxman and
Giasson, 2008).

Other data indicated that polo-like kinase (PLK) 2-mediated

phosphorylation of S129 increased autophagy-mediated degradation of α-synuclein,
suggesting that phosphorylation may be a neuroprotective mechanism to accelerate
clearance of aggregated protein (Oueslati et al., 2013). In addition to the monomeric αsynuclein, S129 phosphorylated bands with apparent molecular weight of 22 kDa and 29
kDa were observed in the detergent insoluble extract (Hasegawa et al., 2002). These
bands were also immunoreactive with anti-ubiquitin antibodies suggesting that S129
phosphorylated α-synuclein is also targeted for mono- and di-ubiquitination. It has long
been established that the core of Lewy bodies stains positive for both α-synuclein and
ubiquitin whereas the surrounding halo is immunoreactive for α-synuclein (Hasegawa et
al., 2002). Of the 15 lysine residues in α-synuclein, the major sites of LB-derived αsynuclein undergoing ubiquitination were residues K12, K21, and K23 (Anderson et al.,
2006; Hasegawa et al., 2002; Sampathu et al., 2003).
A number of spectroscopic methodologies (CD and NMR) were employed to
explore the effect of S129 phosphorylation on the structure of α-synuclein. CD data
revealed that phosphorylation of S129 did not affect secondary structure, such that both
non-phosphorylated

and

phosphorylated S129 exhibited random coil structure
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(Paleologou et al., 2008). NMR data revealed a number of chemical shifts that occur due
to phosphorylation.

While the residues surrounding S129 exhibited the greatest

perturbation, residues 1-90 also exhibited detectable chemical shifts (Paleologou et al.,
2008) This likely reflects the previously documented long-range interactions of the Cand N-termini. The potential effects of phosphorylation of S129 on the structure of the
protein were not faithfully reproduced by mutation of S129 to either E or D, two common
phosphomimics used to study the structural consequences of phosphorylation.

For

example, phosphorylation at S129 increased the hydrodynamic radius of the protein,
whereas S129 E/D mutants did not (Paleologou et al., 2008).
Subsequent studies found additional sites of phosphorylation. Elevated levels of
phosphorylated α-synuclein at residue S87 were detected in human brains with
Alzheimer’s disease, Lewy Body disorders, and multiple system atrophy (Paleologou et
al., 2010).

S87 phosphorylation alters the biophysical properties of α-synuclein,

including inhibition of fibril formation and reduction in membrane binding (Paleologou
et al., 2010). Additionally, phosphorylated α-synuclein at residue Y125 was detected in
Drosophila expressing human wildtype α-synuclein as well as in human brains, though
levels were decreased in disease compared with aged-matched healthy controls (Chen et
al., 2009).
The proximity of the α-synuclein phosphorylation sites to the metal binding sites
raised the question of how phosphorylation may affect metal ion interactions. This was
investigated by the use of C-terminal peptides containing residues 119-132 that were
either unmodified, phosphorylated at Y125 or at S129 (Liu and Franz, 2005).

By

exploiting the luminescence properties of Tb3+, it was found that phosphorylated
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Y125 showed enhanced Tb3+ binding relative to wildtype or phosphorylated S129.
Additionally, phosphorylated Y125 preferentially bound to trivalent rather than divalent
metal ions.

To investigate this further, longer C-terminal fragments comprised of

residues 107-140 that were either unmodified of monophosphorylated at Y125 or S129
were tested for their affinity to various metal ions. By using a fluorescence quenching
assay, the dissociation constants of the metal ion complexes and the α-synuclein peptides
were determined.

These data indicate that either phosphorylation at Y125 or S129

increases the binding affinity for Cu (II) and Fe(II), but not Fe(III).

Furthermore,

phosphorylated Y125 has a greater affinity for Pb(II) than wildtype, but phosphorylated
S129 has an even greater affinity than phosphorylated Y125. Additionally, tandem MS
indicated that phosphorylation causes the metal ion binding sites to shift towards the Cterminal end of α-synuclein (Lu et al., 2011).
α-Synuclein within Lewy bodies is nitrated on all four tyrosine residues (Giasson
et al., 2000). Chemical nitration of α-synuclein results in the formation of both tyrosine
nitrated monomers and nitrated dimers (Souza et al. 2000b).

Immunoelectron

microscopy confirmed that nitrated monomers and dimers are incorporated into amyloid
fibrils.

Purified nitrated α-synuclein monomer by itself was unable to form fibrils,

whereas the nitrated dimer accelerated aggregation of unmodified α-synuclein (Hodara et
al., 2004). Additionally, nitration at residue Y39 in the N-terminus decreased binding to
synthetic vesicles and prevented the protein from adopting α-helical conformation
(Hodara et al., 2004).

These observations were recently confirmed and elegantly

expanded by the generation of site-specifically nitrated α-synuclein using protein
semisynthetic chemistries (Burai et al. 2015).
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Using the synthetic nitrated α-

synuclein the data showed that nitration did not interfere with phosphorylation of S129
by PLK3 and reaffirmed that intermolecular interactions between the N- and C-terminal
regions of α-synuclein are critical in directing nitration-induced oligomerization of αsynuclein (Burai et al. 2015).

3.4.3 Native conformation(s) of α-synuclein
Figure 3.2 depicts the rapid growth in the number of publications identified in
PubMed using the term synuclein and highlights key studies that explored the native
structure and conformation of the protein. Early biochemical studies of α-synuclein
isolated from bacterial expression systems or α-synuclein expressed in rodent tissues
indicated that it is monomeric with limited secondary structure.

Electrophoretic

Figure 3.2: The graph depicts the number of publications retrieved from PubMed using the
search term “alpha synuclein” from a single publication in 1998 to 862 in 2015. Significant
milestones that examined the native structure and conformations of α-synuclein are displayed.
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separation of α-synuclein purified without heating on 6, 10, or 14% acrylamide gels
estimated an apparent molecular weight of 20±3 kDa.

However, the values of

sedimentation coefficient (S20,w = 1.7S), stokes radius (34 Å), analysis on native gels and
derivation of the frictional coefficient (f/fo=2.09) indicated an apparent molecular weight
in the range 57-58 kDa (Weinreb et al., 1996). To reconcile this apparently anomalous
behavior it was proposed that monomeric α-synuclein achieves minimal structure in
simple solutions and this rather extended unstructured conformation resembles a globular
protein with a larger apparent molecular weight.

This assumption was further

corroborated by examination of purified monomeric α-synuclein by CD, FTIR and small
angle X-ray scattering, which failed to identify significant secondary structural features.
Furthermore, minimal shifts in the spectroscopic features of α-synuclein were observed
when the protein was placed in solutions that would increase hydrophobicity and
neutralize negative charges indicating that the protein is natively unstructured, joining a
growing group of proteins sharing similar biochemical and biophysical characteristics
(Uversky et al., 2001b). NMR and CD data, however, indicated that α-synuclein assumes
increasingly folded secondary structure when exposed to conditions that promote
aggregation (low pH and high temperature) or upon interaction with phospholipids.
Collectively these data indicated that native α-synuclein is primarily an unstructured
monomer, which can assume different compact conformations that resist aggregation,
adopts α-helical conformation upon binding to lipids and undergoes conformational
changes prior to oligomerization and formation of amyloid fibrils (Uversky et al., 2001b).
However, the methodologies employed to quantify the molecular weight of α-synuclein
in these elegant studies were not based on first principles and therefore a lingering
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uncertainty remains regarding the native size of the protein. Moreover, crosslinking
experiments in both intact cells expressing α-synuclein and lipid-free lysates revealed the
stabilization of high molecular weight α-synuclein multimers (consistent with dimers,
trimers, and larger multimers). These multimers were not reduced by dilution of lysates
before crosslinking, nor by reducing the concentration of crosslinker from 1 mM to 8
µM, suggesting that they represented endogenous protein complexes (Cole et al., 2002).
Examination of the α-synuclein native state was reignited in 2011 with the
publication of results indicating that α-synuclein exists natively as a tetramer, rather than
a monomer. Methodologies that are based on first principles were employed to examine
the molecular weight and size of α-synuclein extracted under non-denaturing conditions
from human red blood cells. Analytical ultracentrifugation produced a sedimentation
equilibrium value of 4.78 S, indicating a molecular weight of 57.8 kDa. Analysis of
particle geometry by scanning transmission electron microscopy revealed the presence of
roughly spherical molecules with a diameter of approximately 3.0-3.5 nm. Automated
sampling of 1000 α-synuclein particles showed a distribution of molecular weights
between 10 and 175 kDa with a peak distribution at 55 kDa. These findings constitute
the most direct measurements of the native molecular weight of α-synuclein.

The

tetrameric species were shown to have α-helical conformation and were resistant to
aggregation (Bartels et al., 2011).
Complimentary observations were made using recombinant GST-tagged
α-synuclein purified from bacterial expression systems under non-denaturing conditions.
Single-particle electron microscopy of purified α-synuclein revealed complexes of sizes
and internal geometries consistent with trimers
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and

dimers,

which

were

corroborated by measurements of the hydrodynamic radii and elution on native state
PAGE. As observed previously, these species were more resistant to aggregation than
denatured monomer. CD also showed that several α-synuclein mutations associated with
early onset PD (A30P, E46K, A53T) exist in less ordered conformations than wildtype αsynuclein. These mutants were also more prone to aggregation (Wang et al., 2011).
However, using the same α-synuclein construct that contains a 10-residue N-terminal
extension, which forms multimers when isolated from E. coli, NMR studies indicated that
only a small fraction of α-synuclein assembles into α-helical trimers and tetramers and
the majority remains as a disordered monomer (Gurry et al., 2013). These data indicated
that several potential conformers of α-synuclein may exist in equilibrium.

The

observation that α-helical trimers and tetramers constitute only a small fraction of the
total α-synuclein may explain other studies in which in-cell NMR was used to probe for
the structure of α-synuclein and reported primarily the presence of unstructured
monomer. NMR data of α-synuclein in intact cells failed to detect stable or highly
populated α-synuclein multimers and confirmed the intrinsically disordered nature of the
protein in E. coli regardless of its purification method (Binolfi et al., 2012). Collectively
these studies generated an apparent controversy and stimulated several additional studies
that explored the native size and structure of α-synuclein.
A re-examination of the native state of α-synuclein reasserted that the behavior of
α-synuclein from various sources was consistent with a disordered monomer.

This

behavior was observed with protein extracted and isolated under both denaturing and
non-denaturing conditions. CD spectra previously attributed to tetrameric assemblies
were

not

reproduced

using

isolated monomer, but were replicated with the
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addition of small unilamellar vesicles. Natively isolated α-synuclein before or after
boiling that disrupts secondary structure migrated as high molecular weight α-synuclein
bands in native PAGE, which was attributed to the rather expanded size of the
unstructured monomer in solution. These findings reaffirmed that the majority of native
α-synuclein is a monomer with minimal secondary structure (Fauvet et al., 2012a).
Further support was provided by similar explorations in the mouse brain, which indicated
that the predominant native form of α-synuclein is an unstructured monomer.

α-

Synuclein exhibited random coil structure in solution, readily aggregated over time, and
adopted α-helical structure only upon membrane binding (Burré et al., 2013).
α-Synuclein multimers were detected in postmortem non-diseased human brain
using mild protein extraction methods, but no further purification. These α-synuclein
multimers had Stokes radii ranging from 33.2-37.5 Å, sedimentation coefficients ranging
from 1.4S to 3.8S and apparent molecular weights ranging from 53-70 kDa in native
gradient gels. The multimers were detected by anti-α-synuclein antibodies that recognize
different epitopes and the multimer identity was confirmed by mass spectrometry.
Consistent with previous observations, melting point thermostability analysis showed
progressive loss of the α-synuclein multimers and heating of the brain extracts above
55oC collapsed the higher molecular weight α-synuclein conformers into the 53 kDa
species, which corresponds to the unstructured monomer.

These data indicated the

presence of α-synuclein conformers, defined as conformationally diverse α-synuclein
multimers, in the human brain. Therefore it appears that both monomer and metastable
multimers coexist and that interactions with lipids, other proteins, or small molecules
may transiently stabilize these species (Gould et al., 2014).
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This was further

supported by controlled bimolecular fluorescence complementation methodologies in
different cell types that found α-synuclein metastable conformers assembled in synapses.
It was suggested that the function of these multimeric α-synuclein conformers is to
restrict recycling of synaptic vesicles and thus reduce neurotransmitter release (Wang et
al. 2014).
Additional support for native multimeric species comes from recent studies in
which serial purification of α-synuclein from non-pathological human cortical tissue was
performed. Removal of lysate components other than protein followed by sequential
removal of proteins though size exclusion, anion chromatography, and thiopropyl
sepharose 6b separation, resulted in the isolation of >90% pure α-synuclein. Each step of
serial purification resulted in a progressive loss of α-synuclein immunoreactive high
molecular weight bands observed after disuccinimidyl glutarate crosslinking and SDSPAGE separation. Analysis of α-synuclein secondary structure by CD found that the
sequentially purified protein had greater α-helical content than the recombinant αsynuclein. However, a high degree of variability in secondary structure was observed
between purified samples raising questions about the stability of these helical
conformations (Luth et al., 2015). Furthermore, crosslinking experiments conducted in
brain tissue from mice expressing wildtype or A53T human α-synuclein in the absence of
mouse α-synuclein showed that the A53T mutation reduced the presence of soluble
multimeric α-synuclein (Dettmer et al., 2015).

91

3.5 Concluding remarks and perspectives
Collectively the studies on the native structure indicate a remarkable
conformational plasticity and structural flexibility of α-synuclein. The ability of the
protein to adopt N-terminal α-helical conformation through its association with lipids has
been well documented. The association with lipids has been shown to prevent fibril
formation (Martinez et al., 2007; Zhu and Fink, 2003b) and may also stabilize
physiological multimeric species that together with the monomer regulate SNARE
complex assembly and recycling of synaptic vesicles (Burré et al., 2014; Wang et al.
2014). However, other groups have demonstrated a role for phospholipid membranes in
promoting pathological α-synuclein aggregation, potentially by acting as a scaffold for
amyloid nucleation. This event may preferentially occur at low lipid to protein ratios,
when monomeric α-synuclein is free in solution and can participate in nucleation
(Galvagnion et al., 2015; Ysselstein et al., 2015).
In Figure 3.3 we propose a model which incorporates and summarizes the existing
knowledge regarding α-synuclein biology and structure.

The steady state levels of

α-synuclein are carefully regulated by protein synthesis and removal by several pathways
such as the ubiquitin-proteasome pathways and autophagy (Webb et al., 2003).
Controlling the steady state levels of this protein by regulating synthesis and degradation
may be the first critical defense in preventing aggregation. Conformational change to
α-helical rich structures, and stabilization of metastable multimers is achieved by specific
interactions with vesicular phospholipids and proteins. The sequestration of α-synuclein
in association with membrane vesicles and with other proteins may be of critical
importance

for

preventing aggregation. Therefore
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these

dynamic

equilibria

Figure 3.3: Free energy landscape of possible α-synuclein conformers and multimeric
assemblies. The conversion of native α-synuclein to aggregation-competent monomers may
depend on dissociation from stabilizing interactions with lipids and/or proteins as well as
dissociation of the metastable tetrameric species. α-Synuclein aggregation-competent monomers
can then assemble into dimers and larger oligomeric conformers. The generation of α-synuclein
oligomers can rapidly lead to formation of stable amyloid fibrils, or ‘off-pathway’ amorphous
aggregates, both of which have been observed in postmortem brain tissue from patients with PD
and related disorders.

maintain functionality and promote assemblies that are resistant to aggregation.
Catastrophic events that may include inappropriate post-translational modifications will
disassemble the multimers as well as transform aggregation-incompetent monomers to
aggregation-competent species. The first step in the pathway to amyloid fibril formation
is the generation of a dimer that is either held together by hydrophobic interactions
induced by increased conformational transition to β-sheet structure or upon covalent
cross-linking. Following this nucleation event (Wood et al., 1999) the hydrophobic patch
of amino acids between residues 71-82 appears to be primarily responsible for allowing
additional

α-synuclein

monomers

to assemble to form oligomeric structures.
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This transition is the committed rate limiting step for aggregation and must overcome a
relatively large thermodynamic requirement that permits the conversion from an
unstructured coil to organized β-sheet conformation. Oligomers are soluble in aqueous
buffers and can appear spherical or ring-like by atomic force and electron microscopy
(Conway et al., 2000b; Lashuel et al., 2002). Soluble, high molecular weight oligomers
have been extracted from human brain tissue and their levels appear to be increased in
PD brain (Sharon et al., 2003) as well as mouse models of α-synuclein aggregation (Tsika
et al., 2010). As oligomers grow, they reach an undefined critical length and are able to
assume additional quaternary structure. At this stage, these structures may continue to
grow in linear β-sheets, forming polarized protofibrils and eventually fibrils. Fibrils may
further arrange into protein inclusions although it remains unclear if other proteins within
these inclusions anchor these fibrils. Alternatively, oligomers may remain soluble by
interacting with small molecules (Conway et al., 2001) or by incorporating posttranslationally modified α-synuclein molecules. These structures remain “off the amyloid
fibril pathway” and may constitute what has been described in human postmortem tissue
as “dots” or “dust-like” amorphous aggregates (Braak et al., 2001; Duda et al., 2002). At
this juncture, it remains unclear which of these assemblies are toxic to neurons. Recent
data indicate that several conformationally distinct assemblies (possibly different strains)
of α-synuclein generated in vitro will induce the aggregation of endogenous α-synuclein
resulting in neurodegeneration (Guo et al., 2013; Luk et al., 2012; Peelaerts et al., 2015;
Sacino et al., 2014).

The appreciation of different α-synuclein conformers and

assemblies as well as their roles in disease may guide potential therapeutic approaches.
For example, therapeutic strategies can be centered on preserving and stabilizing the
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physiological multimeric conformers as well as preventing monomers from aggregating.
Alternatively, sequestration and removal of aggregation-competent monomers and
oligomers can be considered.
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CHAPTER 4
SUMMARY AND DISCUSSION

96

A pathognomonic hallmark of idiopathic PD is the Lewy body, an intraneuronal
inclusion containing aggregated α-synuclein. Lewy pathology develops in circumscribed
brain regions, and neurodegeneration occurs in several of these areas including the SN
(Forno, 1996; Braak et al., 2003).

Coupled with the discovery that mutations and

multiplications of the α-synuclein gene cause rare forms of familial PD (Goedert et al.,
2013), these defining features suggest that α-synuclein is a major player in PD
pathogenesis. The correlation between Lewy body inclusions and neuronal cell death is
imperfect, however. Not all neuronal populations that harbor α-synuclein inclusions also
exhibit marked cell loss (Forno, 1996). Furthermore the density of inclusions does not
correlate well with clinical severity (Ross and Poirier, 2005). Lewy bodies have also
been found in the brains of some elderly asymptomatic individuals (Goedert et al., 2013).
Mutations in LRRK2, a common cause of familial PD, are not always associated with
Lewy pathology, and juvenile-onset parkinsonism typically develops in the absence of αsynuclein inclusions (Goedert et al., 2013). These observations highlight the need to
better understand the role of α-synuclein aggregation in PD etiology, and raise the
possibility of α-synuclein-independent disease mechanisms.
In sporadic PD, which constitutes the majority of cases, the presence of Lewy
bodies in addition to smaller aggregates of α-synuclein has made it difficult to identify
which species, if any, are primarily responsible for neuronal degeneration. Lewy bodies
and Lewy neurites could present enormous challenges to normal cellular functions,
including protein degradation, axonal transport, and maintenance of the cytoskeleton
(Norris et al., 2004). It is possible that all neurons burdened with α-synuclein deposits
are on a trajectory towards cell death, but due to region- and/or cell type-specific
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factors, neuronal dysfunction and loss manifest with varying kinetics. This may explain
the imperfect correlation between Lewy pathology and neurodegeneration or clinical
symptoms, and suggests that individuals with incidental Lewy body disease may have
preclinical PD (Goedert et al., 2013).

Alternatively, inclusion bodies may serve to

protect neurons by sequestering smaller α-synuclein aggregates such as oligomers or
fibrils, for which there is increasing evidence of toxicity (Danzer et al., 2007; Karpinar et
al., 2009; Tsika et al., 2010; Volpicelli-Daley et al., 2011; Winner et al., 2011; Luk et al.,
2012a). In Chapter 2 of this thesis, I present evidence for a new mouse model of
progressive SN neurodegeneration and locomotor deficit driven by α-synuclein toxicity.
This model was used to examine the relationship of biochemically and histologically
defined α-synuclein aggregates with disease, and I found that dopaminergic neurons
degenerated in the absence of Lewy body-like inclusions. Instead, the disease phenotype
correlated with increased levels of oligomers, which bore similar conformations to
neurotoxic oligomers generated in vitro. Thus, α-synuclein aggregation in multiple brain
regions may give rise to PD specifically through the formation of oligomers. Moreover,
the dependence of both the observed degeneration and oligomer species on dopamine
suggests that catecholamines may enhance α-synuclein toxicity and confer heightened
vulnerability to SN neurons.
Several genes linked to familial PD also implicate mitochondrial dysfunction in
neurodegeneration of the SN and development of parkinsonian signs. Genetic mutations
in Parkin, PINK1, and DJ-1 may converge on a common pathway in which the normal
maintenance and turnover of mitochondria is disrupted (Hernandez et al., 2016). This
may lead to energy depletion, and oxidative stress through increased production of
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reactive oxygen species (Bose and Beal, 2016). Dopaminergic neurons in the SN may be
particularly susceptible to oxidative damage due to the normal metabolism and autooxidation of dopamine (Graham, 1978; Fahn and Cohen, 1992). In support of these
mechanisms, complex I inhibitors such as MPTP induce oxidative stress and reproduce
PD-like dopaminergic cell death in both humans and animal models (Dauer and
Przedborski, 2003). Knockout of Parkin, PINK1, or DJ-1 has been largely insufficient to
induce SN neuron loss in mice (Blesa and Przedborski, 2014), although this may reflect
the slow progression of autosomal recessive PD (Goedert et al., 2013). Critically, the
lack of Lewy body pathology in such cases of PD suggests that this form of the disease
may be mechanistically distinct from the typical late-onset disorder. Toxicity associated
with α-synuclein aggregation may play a more central role in idiopathic PD, although a
potential contribution of α-synuclein to mitochondrial impairment cannot be discounted
since α-synuclein knockout mice are resistant to MPTP (Dauer et al., 2002). The mouse
model presented in Chapter 2 can be used to further investigate potential interactions
between mitochondria, α-synuclein, and dopamine.

In addition, rescue of the

degenerative phenotype by manipulation of putative disease mechanisms, for example
through pharmacological or genetic disruption of toxic interactions or upregulation of
neuroprotective pathways, will inform new strategies for PD treatment.

4.1 The synergistic interaction between dopamine and α-synuclein drives SN
neurodegeneration
In Chapter 2, my findings indicate that nigrostriatal degeneration is dependent on
the convergence of two factors: elevated dopamine and expression of α-synuclein.
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In the mouse brain neither of these factors alone was sufficient to induce neurotoxicity,
suggesting that it is their specific interaction that is required. Given the postulated role of
dopamine in promoting oxidative stress (Graham, 1978; Fahn and Cohen, 1992; Jenner
and Olanow, 1996; Stokes et al., 1999), it is somewhat surprising that long-term elevation
of dopamine levels in NonTg mice did not result in dopaminergic nerve terminal or cell
body loss. Lentiviral-mediated expression of a dysregulated mutant TH achieved a 52%
increase in total striatal dopamine content measured at 5 mpi. It is possible that excess
dopamine was well-tolerated due to compensatory upregulation of metabolic enzymes
and transporters; indeed, there was a significant increase in DAT levels in these mice.
Oxidative stress may be prevented if dopamine storage, release, and re-uptake
mechanisms remain tightly coupled with dopamine levels, for example through the
efficient cycling of excess dopamine into acidified vesicles where its kinetics of oxidation
are much slower than in the cytosol. To my knowledge, this is the first in vivo report of a
sustained increase in dopamine synthesis and the effects on neuronal health. Previous
studies have shown that single, high dose injections of dopamine into the striatum of rats
can be acutely toxic within the short timeframe of 10 days (Filloux and Townsend, 1993;
Hastings et al., 1996; Rabinovic et al., 2000).

Other groups have demonstrated

neurotoxicity associated with redistribution of endogenous dopamine to the cytosol by
manipulation of VMAT2 or DAT in mice (Colebrooke et al., 2006; Caudle et al., 2007;
Chen et al., 2008a; Masoud et al., 2015). While dopamine has been implicated in PD
pathogenesis, its precise role has remained poorly defined.
Despite the clear link between α-synuclein misfolding/aggregation and
neurodegenerative disease in humans, it has
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been

difficult

to

recapitulate these

features in transgenic animal models. The overexpression of human WT or familial
mutant α-synuclein in mice has often resulted in a lack of inclusion pathology and
neurodegenerative changes in the SN (Rathke-Hartlieb et al., 2001; Matsuoka et al.,
2001; Richfield et al., 2002; Giasson et al., 2002; Lee et al., 2002; Gispert et al., 2003;
Gomez-Isla et al., 2003; Yavich et al., 2005; Martin et al., 2006; Emmer et al., 2011). It
is well-established that dopaminergic neurons are entirely spared in the A53T transgenic
mice used in the present work (Giasson et al., 2002) and I also documented a normal
complement of neuronal cell bodies and terminals and a lack of intraneuronal α-synuclein
inclusions in the SN in these mice. This may be related to several factors, including the
fact that WT mouse α-synuclein allele has a threonine at position 53. In vitro, mouse αsynuclein fibrillizes more rapidly than human WT or A53T α-synuclein, and yet aged
mice do not spontaneously develop α-synuclein inclusions or a PD-like disorder (Rochet
et al., 2000). It is likely that mice have evolved protective mechanisms against αsynuclein aggregation, such as an enhanced ability to maintain α-synuclein in a
physiological lipid- or protein-bound state, and that these mechanisms may counteract
efforts to initiate disease by transgenic α-synuclein expression. Given that age is the
greatest risk factor for PD, another possibility is that the short lifespan of mice (typically
1-2 years) does not allow adequate time for development of PD-like inclusions or
neurodegeneration with α-synuclein overexpression.
Strikingly, elevating total striatal dopamine in A53T mice by TH-RREE lentiviral
injection resulted in progressive nigrostriatal degeneration and a locomotor deficit,
suggesting that dopamine dysregulation is a critical factor in α-synuclein mediated
toxicity.

Following an early decrease in

dopaminergic nerve terminals, A53T
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TH-RREE mice exhibited a more severe loss of terminals and overt neuronal cell loss in
the SN at five months after injection. Moreover, there was a time-dependent decline in
dopamine levels that led to a significant reduction in ambulation. These findings are
consistent with other studies in which dopamine and α-synuclein act synergistically to
compromise cellular health. In the case of VMAT2-deficient mice, loss of SN neurons
was only observed in animals on a normal α-synuclein background, whereas identical
reduction of VMAT2 in animals with an α-synuclein gene locus deletion did not result in
cell loss (Specht and Schoepfer, 2001; Colebrooke et al., 2006; Caudle et al., 2007). In
rodent midbrain cultures, elevating cytosolic dopamine concentration reduced
dopaminergic cell survival and this effect was dependent on α-synuclein (Mosharov et
al., 2009). Similarly, both dopamine and α-synuclein were required to induce cell death
in human fetal dopaminergic cultures and SH-SY5Y cells (Xu et al., 2002).
The progressive nature of the phenotype in A53T TH-RREE mice in which
dopaminergic terminals appear to undergo degeneration prior to cell bodies is supported
by existing evidence that synapses are an early site of the disease process. Autopsy
reports as well as PET imaging studies in living PD patients suggest that, at the time of
disease onset, the loss of striatal nerve terminals exceeds that of dopaminergic cell bodies
(Cheng et al., 2010). Axonal pathology containing α-synuclein has also been identified
in PD and DLB (Galvin et al., 1999). Consistent with the human data, expression of
human α-synuclein in the rat SN induced synaptic dysfunction and axonal damage that
preceded substantial cell loss (Chung et al., 2009; Lundblad et al, 2012). My results
show that at the early timepoint of 2.5 mpi, there is a documented 25% loss of
dopaminergic nerve terminals in A53T TH102

RREE mice, without an accompanying

reduction of neuronal cell bodies in the SN. Axonal degeneration progresses such that
dopaminergic innervation of the striatum falls to 62% of age-matched controls, and
coincides with a 25% loss of neurons in the SN. These data are in line with a disease
mechanism that begins at the synapse, causes a ‘dying back’ of axons and a retrograde
progression of neurotoxic events that ultimately lead to neuronal demise. Indeed, the
localization of both dopamine and α-synuclein to presynaptic terminals permits a direct
interaction that may drive neurodegeneration.

4.2 Oligomers are a potential point of convergence for dopamine and α-synuclein
neurotoxicity
The aggregation of α-synuclein can produce several intermediate species and both
fibrillar and non-fibrillar products, and it has been difficult to identify which species may
be relevant to disease. α-Synuclein oligomers are thought to be critical players in PD and
other synucleinopathies (Ross and Poirier, 2005).

Oligomeric species have been

identified and linked with toxicity in cell culture (Gosavi et al., 2002; Outeiro et al.,
2008) and animal models (Tsika et al., 2010; Winner et al., 2011), and appear to be
increased in PD brain (Sharon et al., 2003). Dopamine has been shown to promote
α-synuclein oligomerization both in purified protein systems and cell cultures, through
the non-covalent interaction of oxidized dopamine with the C-terminal 125-YEMPS-129
motif in α-synuclein (Conway et al., 2001; Norris et al., 2005; Mazzulli et al., 2006;
2007). In Chapter 2, I report the novel finding that dopamine increases and modifies
α-synuclein oligomers in the mouse brain, suggesting that dopamine may act as an
enhancer of oligomer toxicity. Presumably,

these changes are mediated by cytosolic
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dopamine, which could encounter and directly interact with α-synuclein, though the
possibility of indirect mechanisms involving vesicular or extracellular dopamine cannot
be excluded. The relevant source of dopamine may be identified by manipulation of
dopamine compartmentalization, for example by co-overexpression of VMAT2, which
would be expected to mitigate α-synuclein oligomerization and neurodegeneration.
Consistent with dopamine-mediated stabilization of α-synuclein oligomers in
vitro (Conway et al., 2001; Norris et al., 2005), elevating total striatal dopamine in A53T
mice resulted in greater levels of oligomeric species. It appears that these species were
primarily generated from monomeric α-synuclein rather than larger aggregates, as
monomer levels were significantly decreased and insoluble α-synuclein remained
unchanged. While it has been reported that dopamine is able to disaggregate α-synuclein
fibrils (Li et al., 2004), this remains to be established and I did not find evidence of
disaggregation in our mouse model. Rather, it is more likely that dopamine acts to shift
the dynamic equilibrium between monomers and oligomers in favor of the oligomeric
state. This could be achieved, for example, through direct interaction with α-synuclein
oligomers, effectively removing them from the reaction, or by interaction with monomers
such that they become aggregation-competent. At present, the exact α-synuclein species
with which dopamine interacts is unknown, although the presence of oxidized dopamine
only in high molecular weight protein complexes extracted from A53T TH-RREE mice
suggests that oligomers may be the likely target.
The oligomer species that result from the interaction of dopamine and α-synuclein
in vivo assume both similar and distinct conformations from those previously observed.
In the SN of A53T control mice, soluble
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oligomers with Stokes radii of up to 65

Å and apparent molecular weights ranging from 36 to 80 kD were identified, entirely
consistent with previous biochemical characterization (Tsika et al., 2010). These low Å
oligomers were also found in A53T TH-RREE mice and appeared more abundant than in
control mice. Interestingly, larger species between 72-122 Å were present only in A53T
TH-RREE mice, and were detected using multiple α-synuclein antibodies by both
western blotting and immunoelectron microscopy. The increase in oligomer size is in
line with the previous observation by atomic force microscopy that larger diameter
particles are produced in vitro when α-synuclein is incubated with dopamine than without
(Follmer et al., 2007). The significance of these findings is two-fold: for the first time it
is demonstrated that dopamine promotes α-synuclein oligomerization in vivo, and
moreover that the resultant species possess unique conformations.

The effects of

dopamine on α-synuclein aggregation may produce neurotoxic species that ultimately
drive neuronal cell death.
The toxicity of dopamine-induced α-synuclein oligomers was tested using
recombinant protein that had been incubated with dopamine in vitro. Soluble, high
molecular weight oligomers resembling mouse-derived species were generated, and
biochemical characterization recapitulated earlier findings (Norris et al., 2005; Cappai et
al., 2005; Pham et al., 2009).

When applied to primary hippocampal cultures, the

recombinant oligomers dose-dependently reduced neuronal viability, whereas neither
oxidized dopamine nor monomeric α-synuclein had the same effect. It is important to
note that several aspects of this experimental paradigm diverge from the mouse model,
including the non-dopaminergic cell type, and the extracellular application of oligomers.
While hippocampal neurons do not mimic
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exactly the physiology and metabolism

of dopaminergic cells, they nonetheless offer a neuronal model in which to test the
sufficiency of α-synuclein oligomers to incur toxicity. The observation that dopamineinduced oligomers were indeed toxic suggests that mechanisms of cell death downstream
of the dopamine-α-synuclein interaction are not dependent on a dopaminergic cellular
phenotype. Regarding the exogenous source of α-synuclein oligomers, there is growing
evidence that α-synuclein aggregates are secreted into the extracellular space and taken
up by neighboring cells where they propagate disease pathology (Lee, 2008; Goedert et
al., 2010).

There is also some evidence that dopamine promotes the secretion of

α-synuclein oligomers (Lee et al., 2011). Exogenous α-synuclein was detected inside
neurons following oligomer treatment, suggesting that dopamine-induced species are able
to translocate across cellular membranes and gain access to nearby cells. A model for the
intracellular formation of these species and possible mechanisms of cell-to-cell spread is
outlined in Figure 4.1.
An alternative approach to test dopamine-induced oligomer toxicity is to disrupt
the interaction between α-synuclein and dopamine, and examine if neuronal loss is
mitigated. This could be achieved by expressing a mutant α-synuclein lacking the Cterminal 125-YEMPS-129 motif that is required for dopamine-mediated stabilization of
oligomers (Norris et al., 2005; Mazzulli et al., 2007).

The small model organism

C. elegans could be utilized for its powerful attributes: a genetically tractable system in
which the entire genome has been sequenced and all neuronal identities have been
mapped, a short generation time and lifespan, transparency which allows for the imaging
of selected cells in living animals, and a repertoire of behaviors that have been associated
with particular neurons or neurotransmitter

systems (Corsi et al., 2015). C. elegans
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Figure 4.1: Model for cell-to-cell transfer of dopamine-induced oligomers. In disease, αsynuclein monomers may be in dynamic equilibrium with aggregated species such as oligomers.
Oxidized dopamine in the cytosol may directly interact with oligomers resulting in modified
conformations with enhanced toxicity. Dopamine-mediated stabilization of these species may
shift the equilibrium towards the formation of additional oligomers, causing an increase in the
total steady-state levels of oligomeric α-synuclein. Dopamine-modified oligomers may propagate
by disruption of synaptic vesicle membranes, allowing dopamine to leak into the cytosol and
interact further with oligomers. These species may also disrupt the plasma membrane gaining
access to the extracellular space, and then directly enter neighboring neurons or become
endocytosed, potentially via receptor-mediated endocytosis. Oligomers may further escape
endosomes by aberrant membrane interactions. Alternatively, dopamine-modified oligomers may
be actively released by dopaminergic neurons by exocytosis, and then taken up by other neurons.
Due to the non-covalent nature of the interaction between α-synuclein and dopamine, oligomers
may eventually be able to participate in the formation of Lewy bodies. The cell-to-cell transfer of
these species as well as other oligomeric conformers may therefore underlie the spread of
pathology and neuronal demise in PD.

that express human WT or A53T mutant α-synuclein in dopaminergic neurons have been
generated and display dopamine neuron dysfunction and loss, as well as motor deficits
(Lakso et al., 2003; Cao et al., 2005; Kuwahara et al. 2006; Cao et al., 2010). Increasing
cytosolic dopamine in WT α-synuclein-expressing worms by mutation of the VMAT2
worm homolog was found to accelerate

neurodegeneration. Conversely, protec107

tion from neuronal loss was reported for worms expressing WT α-synuclein and a nonfunctional homolog of tyrosine hydroxylase and therefore do not synthesize dopamine
(Cao et al., 2010). These studies are entirely consistent with our findings in mice that
indicate dopamine and α-synuclein act together to induce neurodegeneration. To expand
upon this work and test the role of a direct interaction between α-synuclein and
dopamine, worms could be generated expressing human WT or A53T α-synuclein with
the previously described C-terminal 125-FAAFA-129 substitution (Norris et al., 2005;
Mazzulli et al., 2007). These worms would be expected to show amelioration of the
neurodegenerative phenotype and resistance to the neurotoxic effects of increasing
cytosolic dopamine. Moreover, an analysis of α-synuclein oligomers would be expected
to correlate with disease, such that oligomer burden would be increased in α-synuclein/
VMAT2 mutants and decreased in both 125-FAAFA-129 and 125-FAAFA-129/VMAT2
mutants. To my knowledge, oligomeric α-synuclein has not been previously reported in
worm models and these would therefore constitute novel biochemical findings.

4.3 Putative mechanisms of toxicity for dopamine-induced α-synuclein oligomers
Several mechanisms of α-synuclein oligomer toxicity have been proposed,
including disruption of membranes, endoplasmic reticulum stress, mitochondrial
dysfunction, impairment of proteasomal and autophagic degradation, and induction of
neuroinflammation (Roberts and Brown, 2015).

Dopamine-stabilized α-synuclein

oligomers have been shown to impair chaperone-mediated autophagy and SNARE
complex formation in vitro (Martinez-Vicente et al., 2008; Choi et al., 2013). In addition,
toxic α-synuclein aggregates are thought to
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propagate by seeding the conversion of

native α-synuclein into pathological conformations (Goedert et al., 2010). In Chapter 2,
dopamine-modified oligomers extracted from the mouse SN were found to be incapable
of seeding the aggregation of recombinant α-synuclein in an in vitro assay. This is in
contrast to the efficient seeding activity observed for oligomers from control mice,
suggesting that seeding-competent species are not retained following elevation of
dopamine levels in vivo. These data support the notion that dopamine promotes modified
conformations of oligomers, with functional consequences that may be relevant to their
toxicity. Moreover, it appears that toxicity of these species is not mediated through a
seeding mechanism, in contrast to previous reports from A53T mice showing that
seeding-competent oligomers from the spinal cord induced neuronal injury in primary
cultures whereas oligomers from the olfactory bulb that were found to inhibit aggregation
were non-toxic (Tsika et al., 2010). Clearly, further study is warranted to uncover the
relationship between distinct oligomeric conformations, seeding competency, and
neurotoxicity.
An alternative mechanism by which dopamine-induced α-synuclein oligomers
may endanger neuronal health is through the disruption of cellular membranes.
Recombinant α-synuclein oligomers have been shown to bind brain-derived and synthetic
phospholipid membranes and permeabilize synthetic vesicles (Volles et al., 2001; Ding
et al., 2002).

PD-linked A53T and A30P mutations exhibit an enhanced ability to

permeabilize vesicles in vitro (Volles et al., 2002).

In some cases, recombinant

oligomers have displayed ring-like morphologies by electron microscopy and atomic
force microscopy, suggesting that membrane disruption may occur through a poreforming mechanism (Conway et al., 2000b;

Lashuel et al., 2002; Ding et al., 2002).
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Consistent with aberrant membrane interactions, α-synuclein oligomers (in one study,
with annular morphology confirmed) have been shown to increase intracellular calcium
levels and induce caspase activation and cell death when applied to primary neuronal
cultures or SH-SY5Y cells (Danzer et al., 2007; Angelova et al., 2016). The ability of
dopamine-induced oligomers to cause calcium dysregulation has not been explored,
although calcium and α-synuclein were both required for neuronal death in midbrain
cultures following an increase in cytosolic dopamine levels (Mosharov et al., 2009).
To test if recombinant α-synuclein oligomers generated in the presence of
dopamine are able to elevate intracellular calcium, primary hippocampal neurons were
exposed to oligomer preparations following pre-loading with Fluo-4 AM calcium-binding
dye (see Appendix for detailed methods). The extracellular bath contained physiological
concentrations of calcium (1 mM).

Administration of a toxic dose of dopamine-

incubated α-synuclein (1 μM) resulted in an approximately 3% increase in fluorescence
within 5 seconds, and fluorescence remained elevated for at least an additional 15
seconds (Figure 4.2). Interestingly, this effect was observed in axons (Figure 4.2a-b) and
not in cell bodies (Figure 4.2c-d). Equivalent doses of PBS or monomeric α-synuclein
were incapable of producing the same response, indicating that the rise in intracellular
calcium was mediated by oligomers. Furthermore, omission of extracellular calcium
abolished the effect in axons, consistent with oligomer-mediated disruption of membrane
integrity and calcium influx (Figure 4.2a-b). Further investigation is necessary, however,
to exclude the possibility of calcium entry through voltage-gated calcium channels or
glutamate receptors. These data suggest that dopamine-induced α-synuclein oligomers
can interact with cellular membranes and

disturb calcium homeostasis.
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Entirely

consistent with our findings is prior evidence showing that seeding-incompetent αsynuclein oligomers induced calcium influx and cell death in SH-SY5Y cultures while
oligomers that were capable of seeding had no effect on calcium or cell viability (Danzer
et al., 2007). Follow-up experiments could examine the relationship of internalized
oligomers with intracellular membranes and calcium stores.

Figure 4.2: Dopamine-induced α-synuclein oligomers cause calcium dysregulation in
primary neurons. Hippocampal neurons at 7 days in vitro were pre-loaded with Fluo-4 AM dye
and treated with 1 μM α-synuclein oligomer (Olig) or equivalent doses of monomer (Mon),
ionomycin (Ionomyc), or PBS. Representative traces of fluorescence intensity before and after
the time of treatment (indicated by the arrows) are shown. Oligomers induced a significant
increase in fluorescence specifically in axons (a-b) and not in cell bodies (c-d). Exclusion of
calcium from the extracellular bath (Olig -Ca) eliminated the effect of oligomers on axons,
suggesting that oligomers allow calcium entry into cells. The data are presented as mean ± s.e.m.
(Axons, n = 3 except n = 4 for PBS and Olig; Cell bodies, n = 3 except n = 4 for Olig and n = 2
for Ionomycin; one-way ANOVA with Tukey’s correction for multiple comparisons). ***P <
0.001. DEM and HI designed the experiments, VXT collected the data, and VXT and DEM
analyzed the results.
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4.4 Is L-DOPA therapy toxic?
Since the discovery that striatal dopamine is severely depleted in PD patients
(Ehringer and Hornykiewicz, 1960), followed immediately thereafter by the first clinical
use of L-DOPA to replenish dopamine levels (Birkmayer and Hornykiewicz, 1961),
L-DOPA has become the gold standard of PD treatment. Undeniably, the resulting
symptomatic relief has markedly improved patients’ quality of life. However, due to the
notion that dopamine may be neurotoxic, there has been a widespread practice of ‘DOPA
sparing’ that delays administration of the drug until more advanced stages of disease
(Caudle et al., 2008). It is therefore of utmost importance to determine if L-DOPA has
any deleterious effects, in order to inform therapeutic approaches and ensure that patients
receive the best quality of care.
At present, there is no conclusive evidence indicating that L-DOPA therapy
accelerates PD progression (Olanow, 2015). A number of studies have been conducted in
PD patients to test the question of L-DOPA toxicity, including trials based on clinical
outcome (Diamond and Markham, 1990; Fahn et al., 2004; Gray et al., 2014),
neuroimaging markers (Parkinson Study Group, 2002; Whone et al., 2003; Fahn et al.,
2004), and postmortem analyses (Parkkinen et al., 2011). With the exception of the
neuroimaging studies, which found that L-DOPA was associated with an accelerated
decline in dopaminergic markers (Parkinson Study Group, 2002; Whone et al., 2003;
Fahn et al., 2004), the consensus has been that L-DOPA either does not affect PD
progression or in some cases may actually be neuroprotective. However, the results of
these studies are called into question by the significant limitations in their designs and
methodologies. Moreover, the symptomatic
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relief provided by L-DOPA is likely a

confounding factor in the assessment of underlying neuronal health and disease
progression. Thus, the issue of L-DOPA toxicity has unfortunately remained unresolved
(Olanow, 2015).
By the time PD patients manifest motor symptoms and receive L-DOPA
treatment, a significant number of dopaminergic neurons in the SN have already been
lost. In addition, evidence from PD brains suggests that dopaminergic terminals succumb
to disease even earlier than neuronal cell bodies (Cheng et al., 2010), as is also the case in
our mouse model, indicating that much of the disease process has occurred long before
L-DOPA therapy is initiated. While a role for L-DOPA in advancing neurodegeneration
cannot be ruled out, my findings are instead more relevant to the etiology of PD, pointing
to a potential mechanism for the initial demise of dopaminergic neurons involving the
aberrant interaction of oxidized dopamine with α-synuclein.

4.5 Concluding remarks
A unifying theory of neurodegeneration in PD must account for several features
of the disease: the loss of dopaminergic neurons in the SN and the relative sparing of
dopaminergic neurons in the neighboring ventral tegmental area (VTA), the loss of nondopaminergic cells in other brain regions such as the dorsal motor nucleus of the vagus
and the nucleus basalis of Meynert, and the presence of α-synuclein-positive inclusions in
both degenerating and non-degenerating neuronal populations. The work presented in
this thesis offers clues as to the disease mechanisms that may give rise to these features,
and points to novel directions for future research.
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As proposed in Chapter 3, PD may begin when catastrophic events occur allowing
native α-synuclein to become aggregation-competent. These could include age-related
deterioration of proteostasis pathways, such as proper folding of α-synuclein by
chaperones or degradation of improper conformations (Balch et al., 2008). Following
escape from protein quality control mechanisms, α-synuclein may aggregate into
oligomers and fibrils, eventually forming Lewy body inclusions and Lewy neurites. This
may occur independently in different brain regions, or as growing evidence suggests, may
arise through prion-like transmission of α-synuclein across synaptic connections (Goedert
et al., 2010). Different oligomer species can have different levels of toxicity (Danzer et
al., 2007; Tsika et al., 2010), and region-specific factors may determine whether toxic
oligomers are able to form and induce neurodegeneration. In catecholaminergic regions
such as the locus coeruleus and SN, oxidized cytosolic dopamine may act on oligomers
and/or monomers resulting in particularly damaging oligomeric conformations. These
species may then induce cell death potentially through aberrant membrane interactions
and disruption of calcium homeostasis. SN neurons may be more susceptible to calcium
dysregulation than VTA neurons due to their dependence on calcium for pacemaking and
lower intrinsic calcium buffering capacity (Surmeier et al., 2013).
Overall, this thesis provides four novel findings: First, the toxicity of a sustained
elevation in striatal dopamine was tested for the first time, and surprisingly, was
insufficient to produce dopaminergic cell death. Second, and in stark contrast, raising
dopamine levels in the context of higher α-synuclein expression resulted in progressive
nigrostriatal degeneration and a locomotor deficit. Third, for the first time in vivo,
dopamine was shown to promote α-

synuclein
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oligomerization

yielding

species with unique conformations and activity.

Lastly, calcium dysregulation was

implicated as a potential mechanism of dopamine-modified oligomer toxicity.
α-Synuclein oligomers arising from the pathological interaction with dopamine may be
an important new target in the design of disease-modifying therapies.
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APPENDIX

Materials and Methods
Measurement of intracellular calcium was performed as previously described
(Danzer et al., 2007). Briefly, following one week in culture, cells were washed with
Ringer buffer containing 130 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 2 mM
KH2PO4, 5 mM glucose, and 20 mM HEPES. Cells were loaded for 60 min with 2 µM
cell-permeable Fluo-4 AM (Thermo Fisher) in Ringer buffer, then washed with Ringer
buffer, incubated at RT for 30 min, and washed again. Cells were treated with 1 µM
dopamine-incubated α-synuclein (from day 4-6 of in vitro aggregation) or control
treatments. For each well, fluorescence imaging was conducted in the same field of view
for 30 seconds prior to treatment and for up to 5 min total. Intensity measurements were
obtained with MetaMorph software (Molecular Devices) and the baseline was calculated
as the average intensity in the 10 seconds prior to treatment. The ΔF/F was calculated as
(maximum peak height - baseline) / baseline. To determine calcium source, calcium was
excluded from the Ringer buffer and experiments were performed as described above.
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